

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding liver fibrosis:... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-921/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-921" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts.">
            <meta name="og:description" content="Read the latest article version by Ralf Weiskirchen, Sabine Weiskirchen, Frank Tacke, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16154">
            <meta name="article-id" content="14841">
            <meta name="dc.title" content="Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts">
            <meta name="dc.description" content="Hepatic fibrosis is characterized by the formation and deposition of excess fibrous connective tissue, leading to progressive architectural tissue remodeling. Irrespective of the underlying noxious trigger, tissue damage induces an inflammatory response involving the local vascular system and the immune system and a systemic mobilization of endocrine and neurological mediators, ultimately leading to the activation of matrix-producing cell populations. Genetic disorders, chronic viral infection, alcohol abuse, autoimmune attacks, metabolic disorders, cholestasis, alterations in bile acid composition or concentration, venous obstruction, and parasite infections are well-established factors that predispose one to hepatic fibrosis. In addition, excess fat and other lipotoxic mediators provoking endoplasmic reticulum stress, alteration of mitochondrial function, oxidative stress, and modifications in the microbiota are associated with non-alcoholic fatty liver disease and, subsequently, the initiation and progression of hepatic fibrosis. Multidisciplinary panels of experts have developed practice guidelines, including recommendations of preferred therapeutic approaches to a specific cause of hepatic disease, stage of fibrosis, or occurring co-morbidities associated with ongoing loss of hepatic function. Here, we summarize the factors leading to liver fibrosis and the current concepts in anti-fibrotic therapies.">
            <meta name="dc.subject" content="NASH, liver fibrosis, microbiota, therapy, genetic disorders, viral infection, hepatitis, steatosis, collagen.">
            <meta name="dc.creator" content="Weiskirchen, Ralf">
            <meta name="dc.creator" content="Weiskirchen, Sabine">
            <meta name="dc.creator" content="Tacke, Frank">
            <meta name="dc.date" content="2018/06/27">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14841.1">
            <meta name="dc.source" content="F1000Research 2018 7:921">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="NASH">
            <meta name="prism.keyword" content="liver fibrosis">
            <meta name="prism.keyword" content="microbiota">
            <meta name="prism.keyword" content="therapy">
            <meta name="prism.keyword" content="genetic disorders">
            <meta name="prism.keyword" content="viral infection">
            <meta name="prism.keyword" content="hepatitis">
            <meta name="prism.keyword" content="steatosis">
            <meta name="prism.keyword" content="collagen.">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/06/27">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="921">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14841.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-921">
            <meta name="citation_title" content="Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts">
            <meta name="citation_abstract" content="Hepatic fibrosis is characterized by the formation and deposition of excess fibrous connective tissue, leading to progressive architectural tissue remodeling. Irrespective of the underlying noxious trigger, tissue damage induces an inflammatory response involving the local vascular system and the immune system and a systemic mobilization of endocrine and neurological mediators, ultimately leading to the activation of matrix-producing cell populations. Genetic disorders, chronic viral infection, alcohol abuse, autoimmune attacks, metabolic disorders, cholestasis, alterations in bile acid composition or concentration, venous obstruction, and parasite infections are well-established factors that predispose one to hepatic fibrosis. In addition, excess fat and other lipotoxic mediators provoking endoplasmic reticulum stress, alteration of mitochondrial function, oxidative stress, and modifications in the microbiota are associated with non-alcoholic fatty liver disease and, subsequently, the initiation and progression of hepatic fibrosis. Multidisciplinary panels of experts have developed practice guidelines, including recommendations of preferred therapeutic approaches to a specific cause of hepatic disease, stage of fibrosis, or occurring co-morbidities associated with ongoing loss of hepatic function. Here, we summarize the factors leading to liver fibrosis and the current concepts in anti-fibrotic therapies.">
            <meta name="citation_description" content="Hepatic fibrosis is characterized by the formation and deposition of excess fibrous connective tissue, leading to progressive architectural tissue remodeling. Irrespective of the underlying noxious trigger, tissue damage induces an inflammatory response involving the local vascular system and the immune system and a systemic mobilization of endocrine and neurological mediators, ultimately leading to the activation of matrix-producing cell populations. Genetic disorders, chronic viral infection, alcohol abuse, autoimmune attacks, metabolic disorders, cholestasis, alterations in bile acid composition or concentration, venous obstruction, and parasite infections are well-established factors that predispose one to hepatic fibrosis. In addition, excess fat and other lipotoxic mediators provoking endoplasmic reticulum stress, alteration of mitochondrial function, oxidative stress, and modifications in the microbiota are associated with non-alcoholic fatty liver disease and, subsequently, the initiation and progression of hepatic fibrosis. Multidisciplinary panels of experts have developed practice guidelines, including recommendations of preferred therapeutic approaches to a specific cause of hepatic disease, stage of fibrosis, or occurring co-morbidities associated with ongoing loss of hepatic function. Here, we summarize the factors leading to liver fibrosis and the current concepts in anti-fibrotic therapies.">
            <meta name="citation_keywords" content="NASH, liver fibrosis, microbiota, therapy, genetic disorders, viral infection, hepatitis, steatosis, collagen.">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Ralf Weiskirchen">
            <meta name="citation_author_institution" content="Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Pauwelsstra&szlig;e 30, Germany">
            <meta name="citation_author" content="Sabine Weiskirchen">
            <meta name="citation_author_institution" content="Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Pauwelsstra&szlig;e 30, Germany">
            <meta name="citation_author" content="Frank Tacke">
            <meta name="citation_author_institution" content="Department of Medicine III, RWTH University Hospital Aachen, D-52074 Aachen, Pauwelsstra&szlig;e 30, Germany">
            <meta name="citation_publication_date" content="2018/06/27">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="921">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14841.1">
            <meta name="citation_firstpage" content="921">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-921/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-921.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16154 /> <input type=hidden id=articleId name=articleId value=14841 /> <input type=hidden id=xmlUrl value="/articles/7-921/v1/xml"/> <input type=hidden id=xmlFileName value="-7-921-v1.xml"> <input type=hidden id=article_uuid value=a25c7414-568d-4b02-b517-5055f12ed497 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14841.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14841.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-921"
  },
  "headline": "Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts",
  "datePublished": "2018-06-27T15:29:19",
  "dateModified": "2018-06-27T15:29:19",
  "author": [
    {
      "@type": "Person",
      "name": "Ralf Weiskirchen"
    },    {
      "@type": "Person",
      "name": "Sabine Weiskirchen"
    },    {
      "@type": "Person",
      "name": "Frank Tacke"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Hepatic fibrosis is characterized by the formation and deposition of excess fibrous connective tissue, leading to progressive architectural tissue remodeling. Irrespective of the underlying noxious trigger, tissue damage induces an inflammatory response involving the local vascular system and the immune system and a systemic mobilization of endocrine and neurological mediators, ultimately leading to the activation of matrix-producing cell populations. Genetic disorders, chronic viral infection, alcohol abuse, autoimmune attacks, metabolic disorders, cholestasis, alterations in bile acid composition or concentration, venous obstruction, and parasite infections are well-established factors that predispose one to hepatic fibrosis. In addition, excess fat and other lipotoxic mediators provoking endoplasmic reticulum stress, alteration of mitochondrial function, oxidative stress, and modifications in the microbiota are associated with non-alcoholic fatty liver disease and, subsequently, the initiation and progression of hepatic fibrosis. Multidisciplinary panels of experts have developed practice guidelines, including recommendations of preferred therapeutic approaches to a specific cause of hepatic disease, stage of fibrosis, or occurring co-morbidities associated with ongoing loss of hepatic function. Here, we summarize the factors leading to liver fibrosis and the current concepts in anti-fibrotic therapies."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-921/v1",
            "name": "Recent advances in understanding liver fibrosis: bridging basic science..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding liver fibrosis: bridging basic science... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16154 data-id=14841 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14841.1" data-recommended="" data-doi="10.12688/f1000research.14841.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-921/v1/pdf?article_uuid=a25c7414-568d-4b02-b517-5055f12ed497" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14841-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14841-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14841-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Weiskirchen R, Weiskirchen S and Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):921 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14841.1" target=_blank>https://doi.org/10.12688/f1000research.14841.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14841-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14841 id=track-article-signin-14841 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14841?target=/articles/7-921/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16154 /> <input name=articleId type=hidden value=14841 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:rweiskirchen@ukaachen.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ralf Weiskirchen</span></a><a href="https://orcid.org/0000-0003-3888-0931" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3888-0931</div><sup>1</sup>,&nbsp;</span><span class="">Sabine Weiskirchen<sup>1</sup>,&nbsp;</span><span class="">Frank Tacke<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:rweiskirchen@ukaachen.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ralf Weiskirchen</span></a><a href="http://orcid.org/0000-0003-3888-0931" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3888-0931</div><sup>1</sup>,&nbsp;</span><span class="">Sabine Weiskirchen<sup>1</sup>,&nbsp;</span><span class="">Frank Tacke<sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 27 Jun 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14841.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Pauwelsstra&szlig;e 30, Germany<br/> <sup>2</sup> Department of Medicine III, RWTH University Hospital Aachen, D-52074 Aachen, Pauwelsstra&szlig;e 30, Germany<br/> <p> <div class=margin-bottom> Ralf Weiskirchen <br/> <span>Roles: </span> Conceptualization, Supervision, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Sabine Weiskirchen <br/> <span>Roles: </span> Visualization, Writing  Review & Editing </div> <div class=margin-bottom> Frank Tacke <br/> <span>Roles: </span> Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=35869-35411></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=35872-35410></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Hepatic fibrosis is characterized by the formation and deposition of excess fibrous connective tissue, leading to progressive architectural tissue remodeling. Irrespective of the underlying noxious trigger, tissue damage induces an inflammatory response involving the local vascular system and the immune system and a systemic mobilization of endocrine and neurological mediators, ultimately leading to the activation of matrix-producing cell populations. Genetic disorders, chronic viral infection, alcohol abuse, autoimmune attacks, metabolic disorders, cholestasis, alterations in bile acid composition or concentration, venous obstruction, and parasite infections are well-established factors that predispose one to hepatic fibrosis. In addition, excess fat and other lipotoxic mediators provoking endoplasmic reticulum stress, alteration of mitochondrial function, oxidative stress, and modifications in the microbiota are associated with non-alcoholic fatty liver disease and, subsequently, the initiation and progression of hepatic fibrosis. Multidisciplinary panels of experts have developed practice guidelines, including recommendations of preferred therapeutic approaches to a specific cause of hepatic disease, stage of fibrosis, or occurring co-morbidities associated with ongoing loss of hepatic function. Here, we summarize the factors leading to liver fibrosis and the current concepts in anti-fibrotic therapies. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> NASH, liver fibrosis, microbiota, therapy, genetic disorders, viral infection, hepatitis, steatosis, collagen. </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Ralf Weiskirchen (<a href="mailto:rweiskirchen@ukaachen.de">rweiskirchen@ukaachen.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Ralf Weiskirchen </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Work in the laboratory of Frank Tacke has been supported by funding from Tobira Therapeutics, Bristol Myers Squibb, and Galapagos. Ralf Weiskirchen cooperates with Silence Therapeutics. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by the German Research Foundation (DFG, SFB/TRR57) and grants from the Interdisciplinary Centre for Clinical Research (projects O3-1, O3-2) within the Faculty of Medicine at the RWTH Aachen University. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2018 Weiskirchen R <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Weiskirchen R, Weiskirchen S and Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):921 (<a href="https://doi.org/10.12688/f1000research.14841.1" target=_blank>https://doi.org/10.12688/f1000research.14841.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 27 Jun 2018, <b>7</b>(F1000 Faculty Rev):921 (<a href="https://doi.org/10.12688/f1000research.14841.1" target=_blank>https://doi.org/10.12688/f1000research.14841.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 27 Jun 2018, <b>7</b>(F1000 Faculty Rev):921 (<a href="https://doi.org/10.12688/f1000research.14841.1" target=_blank>https://doi.org/10.12688/f1000research.14841.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d46789e180>Introduction</h2><p class="" id=d46789e183>Hepatic fibrosis is a frequent and potentially life-threatening complication associated with most chronic liver diseases, thereby representing a high medical and economic burden. Although major advances in the molecular understanding of liver fibrosis were achieved during the last few decades in a wealth of experimental studies, the translation of this knowledge into clinical practice is still limited. On the one hand, this is somewhat surprising, since the molecular and cellular mechanisms contributing to the pathogenesis of fibrosis are well understood and evolutionarily conserved, independent of the disease-causing noxa. On the other hand, simple pharmacological intervention (fibroprevention, fibrostasis, and fibrolysis) with anti-fibrogenic compounds targeting the fibrogenic matrix is complicated and often effective only in experimental models. In addition, liver fibrosis is not a simple reaction but is the interplay of a multitude of different soluble mediators (cytokines and chemokines) and diverse liver-resident and infiltrating cellular subsets and is further modulated by the chemical and biological properties of the disease-causing agent. In the following, we will briefly summarize the changes induced by these factors and their contribution to the pathogenesis of hepatic fibrosis. In the second part of this synopsis, we will address current strategies in the clinical management of hepatic fibrosis.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d46789e189>Pathogenesis of hepatic fibrosis</h2><p class="" id=d46789e192>The pathogenic sequence of fibrogenesis is initiated by parenchymal cell destruction resulting from a large variety of hepatotoxic and injurious agents and mechanisms. In most cases, the damage of tissue first induces an inflammatory response involving the local vascular system and the immune system and a systemic mobilization of endocrine and neurological mediators. In the mediation of this response, non-parenchymal cells (endothelium and stellate cells) and resident immune cells (macrophages, dendritic cells, and mast cells) possessing specialized surface receptors, which detect pathogen-associated molecular patterns (PAMPs) such as bacterial toxins and damage-associated molecular patterns (DAMPs), are triggered to release a large variety of different inflammatory and pro-fibrogenic mediators within the liver tissue. These lead to the activation of matrix-producing cell populations including hepatic stellate cells (HSCs) transiting to myofibroblasts (MFBs), portal MFBs, resident fibroblasts, and many other cell types contributing to the MFB pool (<a href="#f1">Figure 1</a>)<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Liver fibrosis can be a causative result of different underlying etiologies including genetic disorders, chronic viral infection, excessive alcohol consumption, autoimmune attacks, metabolic disorders, decreased bile flow, venous obstruction, and parasite infection (<a href="#f2">Figure 2</a>). Moreover, excessive lipids and other lipotoxic agents resulting in endoplasmic reticulum stress, alteration of mitochondrial function, oxidative stress in both parenchymal and non-parenchymal liver cells, and modifications in the microbiota composition of the gastrointestinal tract or its integrity are suggested to be associated with non-alcoholic fatty liver disease and hepatic fibrosis<sup><a href="#ref-3">3</a></sup>. The progression of hepatic disease is also triggered by alterations in bile acid composition. Bile acids are amphipathic molecules synthesized in the liver from cholesterol with manifold physiological functions. On the one hand, they facilitate the emulsification of dietary fats and assist the intestinal absorption of lipids and lipophilic vitamins<sup><a href="#ref-4">4</a></sup>. On the other hand, they act like hormones and are embedded in a complex network of signaling cascades. The most important targets of bile acids are the farnesoid X receptor (FXR) and the G-protein-coupled membrane receptor 5 (TGR5), which activate the expression of genes involved in the metabolism of bile acids, lipids, and carbohydrates<sup><a href="#ref-5">5</a></sup>. Importantly, bile acids also have antimicrobial activity that can damage bacterial cell membranes and thus inhibit bacterial overgrowth, protecting the liver and intestine against inflammation.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16154/91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure1.gif"><img alt="91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16154/91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure1.gif"></a><div class=caption><h3>Figure 1. Pathogenesis of hepatic fibrosis.</h3><p id=d46789e231>Prolonged liver injury results in changes in hepatic architecture and advanced fibrosis. At the cellular level, quiescent hepatic stellate cells (HSCs) become triggered by soluble mediators (chemokines and cytokines) released by liver-resident macrophages (Kupffer cells), infiltrating leukocytes, and other cell types including damaged hepatocytes. Both activated HSCs and transdifferentiated myofibroblasts (MFBs) are positive for -smooth muscle actin (-SMA). MFBs are the predominant source of collagen synthesis and deposition. The pool of extracellular matrix (ECM)-producing MFBs is further increased by different cell types such as resident fibroblasts, mesothelial cells, circulating (bone marrow) fibrocytes, epithelial cells, endothelial cells, pericytes, vascular smooth muscle cells, and other specialized cell types that acquire pro-fibrogenic activities and become capable of expressing ECM components. The relevant molecular and cellular mechanisms including epithelial-to-mesenchymal transition (EMT), endothelial-to-mesenchymal transition (EndoMT), mesothelial-to-mesenchymal transition (MMT), recruitment, activation, proliferation, transdifferentiation, and infiltration are being intensively studied presently. For more details, see <a href="#ref-2">2</a>,<a href="#ref-15">15</a>. HBV, hepatitis B virus; HCV, hepatitis C virus.</p></div></div><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16154/91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure2.gif"><img alt="91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16154/91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure2.gif"></a><div class=caption><h3>Figure 2. Major causes of hepatic fibrosis.</h3><p id=d46789e254>In the liver, genetic alterations, metabolic disorders, cholestasis, viral infections, parasites, drugs, toxins, alcohol leading to alcoholic liver disease (ALD), and a wide variety of other noxious compounds and environmental factors can lead to the initiation and progression of fibrosis. AIH, autoimmune hepatitis; CXCR3, C-X-C motif chemokine receptor 3; HBV, hepatitis B virus; HCV, hepatitis C virus; IL28B, interleukin 28B; NASH, non-alcoholic steatohepatitis; PNPLA3, patatin-like phospholipase domain-containing protein 3; RNF7, ring finger protein 7; TGF-, transforming growth factor-.</p></div></div><div class=section><a name=d46789e261 class=n-a></a><h3 class=section-title>Genetic disorders</h3><p class="" id=d46789e266>Nowadays, a number of genetic diseases have been identified to directly or indirectly provoke hepatic fibrogenesis. The affected genes are involved in the control of metal homeostasis, bile acid synthesis or transport, carbohydrate metabolism, amino acid metabolism, the urea cycle, or the regulation of lipid metabolism (<a href="#T1">Table 1</a>). The prevalence, penetrance, age at onset, and disease outcome with regard to hepatic fibrosis can be significantly variable for the different triggers. Although metals play a host of pivotal roles in the liver by either being part of protein complexes or acting as essential cofactors and catalysts, elevated concentrations of metals result in intracellular reactive oxygen species (ROS) formation, induction of necrosis and apoptosis, and release or synthesis of pro-fibrogenic soluble mediators<sup><a href="#ref-6">6</a></sup>. Elevated iron concentrations are the characteristic result in hereditary hemochromatosis provoked by mutations within the <i>HFE</i> gene or other genes (<i>SLC40A1</i>, <i>TFR2</i>, <i>HAMP</i>, and <i>HJV</i>) controlling iron homeostasis<sup><a href="#ref-7">7</a></sup>. Likewise, hepatic damage in Wilson's disease affecting the uptake and clearance of ingested copper is induced by mutations within the <i>ATP7B</i> gene<sup><a href="#ref-8">8</a></sup>. Genetic disorders associated with functional alterations of ATP-binding cassette (ABC) transporters utilizing the energy of ATP binding and hydrolysis in the participation of hepatobiliary transport of metabolites, phospholipids, and cholesterol and different bile acid translocation of various substrates across cellular membranes can provoke fibrosis when failing to protect the cells from endogenously produced toxic compounds and metabolites. These genetic disorders might provoke familial hypercholesterolemia (<i>ABCG5</i> and <i>ABCG8</i>), progressive familial intrahepatic cholestasis type 3 (<i>ABCB4</i>), cystic fibrosis liver disease (<i>CFTR</i>), general hepatic manifestation, or injury of the hepatobiliary system<sup><a href="#ref-9">9</a></sup>. Moreover, mutations affecting genes involved in amino acid synthesis or catabolism including fumarylacetoacetate hydrolase 1 (<i>FAH</i>), arginosuccinate lyase (<i>ASL</i>), and solute carrier family 25 member 13 (<i>SLC25A13)</i> are prone to induce hepatic fibrogenesis. Another group of genes associated with hepatic fibrogenesis contains metabolic genes affecting cholesterol metabolism (<i>LIPA</i>) or fructose intolerance (<i>ALDOB</i>), in which alterations can provoke liver fibrosis due to a massive accumulation of cholesteryl esters or sugars<sup><a href="#ref-10">10</a><a href="#ref-12">12</a></sup>. In 1-antitrypsin deficiency, point mutations are the cause of misfolded and polymerized protein accumulating in the endoplasmic reticulum of hepatocytes, causing liver disease and hepatic fibrosis in children and adults<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Selected inherited disorders associated with hepatic fibrosis.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d46789e361 class=n-a></a><thead><a name=d46789e363 class=n-a></a><tr><a name=d46789e365 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e367 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e370 class=n-a></a>Gene</th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e373 class=n-a></a>OMIM/cytogenetic<br class=br>location</th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e378 class=n-a></a>Prevalence<a href="#FN1">*</a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e383 class=n-a></a>Remarks</th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e387 class=n-a></a>Reference</th></tr></thead><tbody><a name=d46789e392 class=n-a></a><tr><a name=d46789e394 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e396 class=n-a></a>Wilson's disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e399 class=n-a></a>ATP7B</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e402 class=n-a></a>606882 / 13q14.3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e405 class=n-a></a>19:100,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e408 class=n-a></a>ATPase, plasma membrane copper-transport<br class=br>protein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e414 class=n-a></a><a href="#ref-8">8</a></td></tr><tr><a name=d46789e419 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e421 class=n-a></a>Hereditary<br class=br>hemochromatosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e426 class=n-a></a>HFE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e429 class=n-a></a>613609 / 6p22.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e432 class=n-a></a>35:1,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e435 class=n-a></a>Membrane protein with similarity to major<br class=br>histocompatibility complex class I proteins;<br class=br>associates with transferrin receptor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e443 class=n-a></a><a href="#ref-7">7</a></td></tr><tr><a name=d46789e448 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e450 class=n-a></a>Non-HFE hereditary<br class=br>hemochromatosis<br class=br>Ferroportin<br class=br><br class=br>Transferrin receptor 2<br class=br><br class=br>Hepcidin<br class=br><br class=br>Hemojuvelin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e467 class=n-a></a><br class=br><br class=br>SLC40A1<br class=br><br class=br>TFR2<br class=br><br class=br>HAMP<br class=br><br class=br>HJV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e481 class=n-a></a><br class=br><br class=br>604653 / 2q32.2<br class=br><br class=br>604720 / 7q22.1<br class=br><br class=br>606464 / 19q13.12<br class=br><br class=br>608374 / 1q21.1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e495 class=n-a></a><br class=br><br class=br>&lt;1:1,000,000<br class=br><br class=br>&lt;1:1,000,000<br class=br><br class=br>&lt;1:1,000,000<br class=br><br class=br>&lt;1:1,000,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e509 class=n-a></a><br class=br><br class=br>Transmembrane protein transporting cellular iron<br class=br>from the inside to the outside<br class=br>Involved in cellular uptake of transferrin-bound<br class=br>iron<br class=br>Key regulator of entry of iron into the circulation<br class=br><br class=br>Co-receptor for bone morphogenetic proteins</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e527 class=n-a></a><a href="#ref-7">7</a></td></tr><tr><a name=d46789e532 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e534 class=n-a></a>Sitosterolemia<br class=br>/ Hepatobiliary<br class=br>cholesterol<br class=br>transporter 5 and 8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e543 class=n-a></a>ABCG5<br class=br>ABCG8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e548 class=n-a></a>605459 / 2p21<br class=br>605460 / 2p21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e553 class=n-a></a>19:1,000,000<br class=br>19:1,000,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e558 class=n-a></a>ATP-binding cassette transporters encoding<br class=br>major susceptibility genes for gallstones</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e564 class=n-a></a><a href="#ref-9">9</a></td></tr><tr><a name=d46789e569 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e571 class=n-a></a>Progressive familial<br class=br>intrahepatic<br class=br>cholestasis type 3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e578 class=n-a></a>ABCB4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e581 class=n-a></a>171060 / 7q21.12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e584 class=n-a></a>19:100,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e587 class=n-a></a>ATP-binding cassette transporters encoding a<br class=br>multidrug-resistance protein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e593 class=n-a></a><a href="#ref-28">28</a></td></tr><tr><a name=d46789e599 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e601 class=n-a></a>Hereditary fructose<br class=br>intolerance</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e606 class=n-a></a>ALDOB</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e609 class=n-a></a>612724 / 9q31.1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e612 class=n-a></a>19:100,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e615 class=n-a></a>Liver-type tetrameric aldolase involved in<br class=br>glycolysis and gluconeogenesis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e621 class=n-a></a><a href="#ref-12">12</a></td></tr><tr><a name=d46789e626 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e628 class=n-a></a>Tyrosinemia type I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e631 class=n-a></a>FAH</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e634 class=n-a></a>613871 / 15q25.1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e637 class=n-a></a>1:100,000 (birth<br class=br>incidence)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e642 class=n-a></a>Enzyme involved in catabolism of phenylalanine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e646 class=n-a></a><a href="#ref-10">10</a></td></tr><tr><a name=d46789e651 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e653 class=n-a></a>Argininosuccinate<br class=br>lyase deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e658 class=n-a></a>ASL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e661 class=n-a></a>608310 / 7q11.21</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e664 class=n-a></a>19:100,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e667 class=n-a></a>Enzyme catalyzing the production of arginine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e671 class=n-a></a><a href="#ref-11">11</a></td></tr><tr><a name=d46789e676 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e678 class=n-a></a>Citrin deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e681 class=n-a></a>SLC25A13</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e684 class=n-a></a>603859 / 7q21.3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e687 class=n-a></a>NN</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e690 class=n-a></a>Calcium-dependent mitochondrial solute<br class=br>transporter with a role in urea cycle function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e696 class=n-a></a><a href="#ref-29">29</a></td></tr><tr><a name=d46789e701 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e703 class=n-a></a>Cholesteryl ester<br class=br>storage disease and<br class=br>Wolman disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e710 class=n-a></a>LIPA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e713 class=n-a></a>613497 / 10q23.31</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e716 class=n-a></a>19:1,000,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e719 class=n-a></a>Enzyme involved in the preduodenal breakdown<br class=br>of ingested triglycerides</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e725 class=n-a></a><a href="#ref-30">30</a></td></tr><tr><a name=d46789e730 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e732 class=n-a></a>-1 antitrypsin<br class=br>deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e737 class=n-a></a>SERPINA1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e740 class=n-a></a>613497 / 10q23.31</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e743 class=n-a></a>15:10,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e746 class=n-a></a>Plasma serine protease inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e750 class=n-a></a><a href="#ref-14">14</a>,<a href="#ref-31">31</a></td></tr><tr><a name=d46789e759 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e761 class=n-a></a>Cystic fibrosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e764 class=n-a></a>CFTR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e767 class=n-a></a>602421 / 7q31.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e770 class=n-a></a>19:100,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e773 class=n-a></a>ATP-binding cassette transporter conducting<br class=br>chloride and thiocyanate ions across epithelial<br class=br>cell membranes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e781 class=n-a></a><a href="#ref-32">32</a></td></tr><tr><a name=d46789e786 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e788 class=n-a></a>Alstrm syndrome</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e791 class=n-a></a>ALMS1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e794 class=n-a></a>606844 / 2p13.1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e797 class=n-a></a>19:1,000,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e800 class=n-a></a>Protein involved in ciliary function and structure<br class=br>maintenance</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e806 class=n-a></a><a href="#ref-33">33</a></td></tr><tr><a name=d46789e811 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e813 class=n-a></a>(Isolated) congenital<br class=br>hepatic fibrosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e818 class=n-a></a>NN</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e821 class=n-a></a>NN / NN</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e824 class=n-a></a>0.51:10,000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e827 class=n-a></a>Developmental disorder of the portobiliary<br class=br>system characterized histologically by defective<br class=br>remodeling of the ductal plate, abnormal<br class=br>branching of the intrahepatic portal veins, and<br class=br>progressive fibrosis of the portal tracts; heredity:<br class=br>autosomal recessive, or X-linked, or autosomal<br class=br>dominant.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e844 class=n-a></a><a href="#ref-34">34</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d46789e853 class=n-a></a><p id=FN1> *Depicted frequencies were taken from Orphanet (<a target=xrefwindow href="http://www.orpha.net/" id=d46789e857>http://www.orpha.net/</a>), GeneReviews (<a target=xrefwindow href="https://www.ncbi.nlm.nih.gov/books/NBK1116/" id=d46789e860>https://www.ncbi.nlm.nih.gov/books/NBK1116/</a>), or the National Organization of Rare Disorders (<a target=xrefwindow href="https://rarediseases.org/" id=d46789e863>https://rarediseases.org</a>). NN, not known; OMIM, Online Mendelian Inheritance in Man.</p></div></div></div></div><div class=section><a name=d46789e872 class=n-a></a><h3 class=section-title>Cholestasis</h3><p class="" id=d46789e877>Cholestatic liver disease and disruption of proper bile secretion leads to liver damage, inflammation, and fibrosis. Mechanistically, hepatic accumulation of bile compounds consisting of salts and strong detergents causes unspecific cellular damage and initiation of a cascade of inflammatory and fibrogenic events in the liver. Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), biliary atresia, or loss-of-function mutations such as those found in Alagille syndrome affecting the <i>JAG1</i> or <i>NOTCH2</i> genes are only some causes of impaired bile flow by the liver<sup><a href="#ref-16">16</a></sup>. Moreover, direct mechanical obstruction of the bile flow from the liver into the duodenum, termed extrahepatic cholestasis, caused by neoplastic invasion of the biliary tree (e.g. cancers of extrahepatic bile ducts, gallbladder, or ampulla of Vater), cysts, stones in the common bile duct, pancreatitis, or narrowing of the bile duct can provoke impairment of bile flow and induce hepatic fibrosis<sup><a href="#ref-17">17</a></sup>.</p></div><div class=section><a name=d46789e895 class=n-a></a><h3 class=section-title>Alcohol</h3><p class="" id=d46789e900>An overwhelming number of patients with excessive alcohol consumption and alcoholic hepatitis present with marked fibrosis<sup><a href="#ref-18">18</a></sup>. In alcoholic liver disease, the fibrogenic response in the liver after the uptake of alcohol is driven by acetaldehyde. Acetaldehyde is the first metabolite during the detoxification of ethanol, which can upregulate the transcription of collagen I directly and indirectly by triggering the synthesis of transforming growth factor-1 (TGF-1)<sup><a href="#ref-19">19</a></sup>. Moreover, chronic intake of alcohol provokes ROS formation, increases the multiplication of intestinal bacteria, and changes the intestines permeability to macromolecules, thereby increasing gut-derived endotoxins in the portal circulation and activating Kupffer cells through the Toll-like receptor pathways<sup><a href="#ref-20">20</a></sup>.</p></div><div class=section><a name=d46789e916 class=n-a></a><h3 class=section-title>Hepatitis virus infection</h3><p class="" id=d46789e921>Infections with hepatitis B or C viruses are a global health problem associated with significant mortality and account for more than 1.3 million deaths per year and highly variable regional incidence rates and gender susceptibility for resulting complications<sup><a href="#ref-21">21</a><a href="#ref-23">23</a></sup>. Both infections are characterized by persistent hepatic inflammation, representing an important driver in establishing fibrosis and cirrhosis. Earlier studies estimated that, globally, 57% of cirrhosis and 78% of hepatocellular carcinoma cases are attributable to chronic infection with either hepatitis B or hepatitis C<sup><a href="#ref-24">24</a></sup>. Antiviral treatment strategies and the general introduction of effective hepatitis B vaccination have reduced the burden of hepatitis B<sup><a href="#ref-25">25</a></sup>, while the introduction of direct antiviral agents against hepatitis C virus offers the option to cure the disease worldwide<sup><a href="#ref-26">26</a></sup>.</p></div><div class=section><a name=d46789e944 class=n-a></a><h3 class=section-title>Drugs</h3><p class="" id=d46789e949>Drug-induced liver injury (DILI) is one of the leading causes of acute liver failure in the Western world, with paracetamol (acetaminophen [APAP]) being the commonest causative drug followed by antimicrobials<sup><a href="#ref-27">27</a></sup>. The pattern of DILI-related hepatotoxicity is classified as hepatocellular, cholestatic, or mixed type. DILI can, in rare cases, also result in fibrosis or other patterns of chronic injury such as nodular regenerative hyperplasia, vanishing bile duct syndrome, or even cirrhosis<sup><a href="#ref-27">27</a></sup>.</p></div><div class=section><a name=d46789e961 class=n-a></a><h3 class=section-title>Autoimmune disorders</h3><p class="" id=d46789e966>Autoimmune diseases of the liver can affect either the liver parenchyma (autoimmune hepatitis [AIH]) or the bile ducts (PBC and PSC). The overwhelming immune reaction promotes progressive destruction of the parenchyma, further inflammation, loss of hepatic function, and fibrosis<sup><a href="#ref-35">35</a></sup>. Based on the type of autoantibodies generated, three types of autoimmune hepatitis are historically classified. Patients with type 1 AIH are characterized by the presence of anti-nuclear antibodies and/or antibodies directed against smooth muscle actin. Serum from type 2 AIH patients contains antibodies directed against microsomes of liver and kidney, and serum from type 3 AIH patients typically contains auto-antibodies directed against soluble liver antigen<sup><a href="#ref-35">35</a></sup>. In PBC, more than 60 auto-antibodies were identified from which the presence of anti-mitochondrial antibodies is pathognomonic, while anti-nuclear antibodies are found in approximately half of patients<sup><a href="#ref-36">36</a></sup>. Likewise, in PSC patients, a large variety of auto-antibodies were detected which react with epitopes present in the mitochondria or nuclei of biliary or colonic epithelial cells, neutrophil granules, or ubiquitously expressed compounds<sup><a href="#ref-37">37</a></sup>. However, the exact pathogenesis of PSC is largely obscure, and the disease is characterized by progressive fibrotic fibers around bile ducts, recurrent episodes of bacterial cholangitis, and a high risk for malignant transformation<sup><a href="#ref-38">38</a></sup>. Overlapping features between AIH and cholestatic disorders such as PBC, PSC, or indeterminate cholestasis, known as overlap syndromes, are not uncommon. The diagnosis of AIH and its overlap variants are based on an integrated analysis of symptoms, clinical findings, biochemical tests, serologic features, and liver histology<sup><a href="#ref-39">39</a></sup>.</p></div><div class=section><a name=d46789e995 class=n-a></a><h3 class=section-title>Nutrition and metabolic diseases</h3><p class="" id=d46789e1000>Over-nutrition, obesity, and its multiple metabolic sequelae, including type 2 diabetes mellitus, heart and blood vessel diseases, and fatty liver disease, are advancing worldwide, especially in the Western countries. Insulin resistance and hepatic fat deposition accompanied by steatosis, lipotoxicity, endoplasmic reticulum stress, parenchymal injury, and death are triggering hepatic inflammation, HSC activation, and progressive fibrogenesis<sup><a href="#ref-40">40</a></sup>. Recent evidence further suggests that diets enriched in sugar are also key in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by impacting gut microbiota and triggering hepatic fat accumulation due to the stimulation of lipogenesis and impairment of fat oxidation<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. Contrarily, several bioactive food components such as caffeine, vitamins, curcumin, silymarin, resveratrol, quercetin, epigallocatechin-3-gallate, and many others are known to protect against hepatic fibrosis<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>. Recently, the gut microbiota has been considered as a key modulator of host metabolism. The gut microbiota not only facilitates the harvesting of nutrients and energy from ingested food but also is essential in the production of numerous metabolites necessary for proper host metabolism, including bile acids, which regulate diverse metabolic pathways in the host<sup><a href="#ref-5">5</a></sup>.</p></div><div class=section><a name=d46789e1027 class=n-a></a><h3 class=section-title>Gut microbiota</h3><p class="" id=d46789e1032>The integrity of the intestinal barrier is highly crucial to the function of the gutliver axis. A leaky gut and a pathological translocation of bacteria or bacterial components resulting from quantitative or qualitative changes in the gut microbiota (dysbiosis) lead to the activation of resident liver macrophages (i.e. Kupffer cells) releasing pro-inflammatory cytokines and stimulation of matrix synthesis by HSCs through Toll-like receptors<sup><a href="#ref-45">45</a></sup>. Changes in the gut microbiome detected in non-invasive, stool-based tests were recently shown to be clinically useful to diagnose metabolic diseases and advanced fibrosis in patients with NAFLD<sup><a href="#ref-46">46</a></sup>. In addition, there is a correlation among gut microbiota composition, alcohol, and ROS formation (see above).</p></div><div class=section><a name=d46789e1044 class=n-a></a><h3 class=section-title>Venous obstruction</h3><p class="" id=d46789e1049>Obstruction of the portal venous flow can result from intrahepatic or extrahepatic portal vein thrombosis or portal cavernoma. General risk factors for portal vein thrombosis are reduced portal flow velocity, hypercoagulable tendency, vascular damage, and malignant vascular invasion<sup><a href="#ref-47">47</a></sup>. Hepatic venous outflow obstruction typically provokes sinusoidal congestion and parenchymal cell necrosis mostly in perivenular areas of hepatic acini, which may lead to the formation of bridging fibrosis between adjacent central veins<sup><a href="#ref-48">48</a></sup>. The disease is complex and the obstruction might occur in the small veins in the liver (veno-occlusive disease) or in the draining liver veins (Budd-Chiari syndrome) or is the result of increased pressure in the sublobular branches of hepatic veins due to chronic heart failure (congestive hepatopathy). When not properly treated, chronic obstruction leads to ischemic necrosis, subsequent collagen accumulation, and regional vein wall remodeling.</p></div><div class=section><a name=d46789e1061 class=n-a></a><h3 class=section-title>Parasites</h3><p class="" id=d46789e1066>The most important parasitic diseases associated with liver fibrosis are schistosomiasis and echinococcosis. Hydatid cysts arising from <i>Echinococcus granulosus</i> or <i>Echinococcus multilocularis</i> and granulomas formed around trapped eggs during infection with <i>Schistosoma mansoni</i> and <i>Schistosoma japonicum</i> give rise to fibrosis around the trapped parasitic invader component resulting from host immune responses<sup><a href="#ref-49">49</a></sup>. Experimental studies have shown that hepatic hydatidosis due to <i>E. granulosus</i> infection results in increased TGF-1 mRNA and protein expression in the middle and late stages of infection and stimulates the development of hepatic fibrosis<sup><a href="#ref-50">50</a></sup>. Similarly, a study analyzing 39 patients with cystic echinococcosis revealed that the TGF- receptor II occupying a central role in the transduction of TGF-1 signals was significantly upregulated in <i>E. granulosus</i>-infected areas when compared with the adjacent normal liver tissues<sup><a href="#ref-51">51</a></sup>.</p></div><div class=section><a name=d46789e1101 class=n-a></a><h3 class=section-title>Cryptogenic and congenital liver disease</h3><p class="" id=d46789e1106>Typically, cryptogenic development of hepatic fibrosis and cirrhosis occurs in mid to late adulthood as a result of inherited disorders. In some cases, mutations in certain cytokeratin proteins (keratin 18 and keratin 8) are associated with the pathogenesis of cryptogenic and congenital liver disease. In this regard, conserved amino acids located at the junctures between individual structural motifs within keratins are most effective in producing hepatic fibrosis and cirrhosis by interfering with the normal reorganization of keratin filaments<sup><a href="#ref-52">52</a></sup>. Other reports suggested cryptogenic liver disease as a consequence of unidentified mutation within ABC transporters involved in limiting intestinal absorption and promoting biliary excretion of sterols, such as the <i>ABCG5</i> (Sterolin-1) and <i>ABCG8</i> (Sterolin-2) genes<sup><a href="#ref-53">53</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d46789e1127>Existing and emerging therapies for hepatic fibrosis</h2><p class="" id=d46789e1130>There are a large number of sound clinical practice guidelines and recommendations for the treatment of patients with hepatic fibrosis, according to the different types of liver diseases. Naturally, these guidelines focus on etiology-specific interventions or on the management of disease complications but do not recommend general anti-fibrotic therapies (<a href="#T2">Table 2</a>). The clinical treatment guidelines from professional associations such as the American Association for the Study of Liver Diseases (AASLD) or the European Association for the Study of the Liver (EASL) are important to improve the consistency and quality of care received by patients. In addition to these standardized guidelines, complementary and alternative therapies, herbal products, vitamins, or other dietary supplements are widely applied in patients suffering from chronic liver disease (<a href="#f3">Figure 3</a>). In the following, we will briefly sum up the current treatment regimens and the pathogenic basis of anti-fibrotic properties of specific treatments in hepatic fibrosis based on either experimental data or, in selected cases, clinical evidence.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Selected strategies for treatment of hepatic fibrosis according to disease etiology.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d46789e1150 class=n-a></a><thead><a name=d46789e1152 class=n-a></a><tr><a name=d46789e1154 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e1156 class=n-a></a>Noxa</th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e1159 class=n-a></a>Treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e1162 class=n-a></a>Consequence of treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d46789e1165 class=n-a></a>Reference</th></tr></thead><tbody><a name=d46789e1170 class=n-a></a><tr><a name=d46789e1172 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1174 class=n-a></a>Hemochromatosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1177 class=n-a></a>Phlebotomy or chelating therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1180 class=n-a></a>Reduction of iron content</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1183 class=n-a></a><a href="#ref-54">54</a></td></tr><tr><a name=d46789e1188 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1190 class=n-a></a>Wilson's disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1193 class=n-a></a>Chelating therapy and zinc supplementation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1196 class=n-a></a>Reduction of copper content and uptake</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1199 class=n-a></a><a href="#ref-55">55</a></td></tr><tr><a name=d46789e1204 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1206 class=n-a></a>Sitosterolemia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1209 class=n-a></a>Dietary restriction of cholesterol and plant sterols, sterol absorption<br class=br>inhibitors</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1214 class=n-a></a>Reduction of plasma plant sterols and cholesterol<br class=br>concentrations</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1219 class=n-a></a><a href="#ref-9">9</a></td></tr><tr><a name=d46789e1224 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1226 class=n-a></a>Progressive familial<br class=br>intrahepatic cholestasis<br class=br>type 3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1233 class=n-a></a>Nutritional support with calories, fat-soluble vitamins, and medium-chain<br class=br>triglycerides; medications to relieve pruritus; liver transplantation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1238 class=n-a></a>Relief from pruritus, improvement of nutritional status,<br class=br>correction of vitamin deficiencies and treatment of<br class=br>complications (ascites and variceal bleeding) of advanced<br class=br>liver disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1247 class=n-a></a><a href="#ref-28">28</a></td></tr><tr><a name=d46789e1252 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1254 class=n-a></a>Hereditary fructose<br class=br>intolerance</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1259 class=n-a></a>Dietary restriction of fructose, sucrose, and sorbitol intravenous glucose<br class=br>(dextrose) administration, supportive treatment of hepatic insufficiency,<br class=br>and treatment of metabolic acidosis; supplementation with a "sugar-free"<br class=br>multivitamin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1268 class=n-a></a>Reduction of toxic sugar effects, prevention of micronutrient<br class=br>deficiencies</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1273 class=n-a></a><a href="#ref-56">56</a></td></tr><tr><a name=d46789e1279 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1281 class=n-a></a>Tyrosinemia type I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1284 class=n-a></a>Dietary management with controlled intake of phenylalanine and tyrosine;<br class=br>medication with blockers of parahydroxyphenylpyruvic acid dioxygenase<br class=br>(<i>p</i>-HPPD)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1294 class=n-a></a>Prevention of the accumulation of fumarylacetoacetate and<br class=br>its conversion to succinylacetone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1299 class=n-a></a><a href="#ref-57">57</a></td></tr><tr><a name=d46789e1304 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1306 class=n-a></a>Argininosuccinate lyase<br class=br>deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1311 class=n-a></a>Control of hyperammonemia by discontinuing oral protein intake,<br class=br>supplementing oral intake with intravenous lipids and/or glucose, and use of<br class=br>intravenous arginine and nitrogen-scavenging therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1318 class=n-a></a>Reduction and normalization of ammonia levels</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1321 class=n-a></a><a href="#ref-58">58</a></td></tr><tr><a name=d46789e1326 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1328 class=n-a></a>Citrin deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1331 class=n-a></a>Supplement diet with fat-soluble vitamins and use of lactose-free and<br class=br>medium-chain triglyceride-enriched formula; administration of sodium<br class=br>pyruvate and arginine; liver transplantation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1338 class=n-a></a>Prevention of hyperammonemic crises, correction of<br class=br>metabolic disturbances, and elimination of preferences for<br class=br>protein-rich foods</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1345 class=n-a></a><a href="#ref-29">29</a></td></tr><tr><a name=d46789e1350 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1352 class=n-a></a>Cholesteryl ester storage<br class=br>disease and Wolman<br class=br>disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1359 class=n-a></a>Long-term enzyme replacement therapy with lysosomal acid lipase;<br class=br>hematopoietic stem cell transplantation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1364 class=n-a></a>Correction of the metabolic defect</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1367 class=n-a></a><a href="#ref-59">59</a></td></tr><tr><a name=d46789e1372 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1374 class=n-a></a>-1 antitrypsin deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1377 class=n-a></a>Orthotopic liver transplantation; augmentation therapy (against pulmonary<br class=br>diseases); RNA interference-based therapeutics silencing the production of<br class=br>misfolded protein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1384 class=n-a></a>Reduction of misfolded protein; increase of serum -1<br class=br>antitrypsin levels</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1389 class=n-a></a><a href="#ref-14">14</a>,<a href="#ref-31">31</a></td></tr><tr><a name=d46789e1397 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1399 class=n-a></a>Cystic fibrosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1402 class=n-a></a>Optimization of nutritional state to avoid vitamin deficiency and malnutrition;<br class=br>medication with ursodeoxycholic acid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1407 class=n-a></a>Stimulation of impaired biliary secretion and improvement<br class=br>of histological appearance</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1412 class=n-a></a><a href="#ref-60">60</a>,<a href="#ref-61">61</a></td></tr><tr><a name=d46789e1421 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1423 class=n-a></a>Alstrm syndrome</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1426 class=n-a></a>Nicotinic acid derivatives for hyperlipidemia, lifestyle changes;<br class=br>individualized therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1431 class=n-a></a>Lowering of lipids</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1434 class=n-a></a><a href="#ref-62">62</a>,<a href="#ref-63">63</a></td></tr><tr><a name=d46789e1442 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1444 class=n-a></a>(Isolated) congenital<br class=br>hepatic fibrosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1449 class=n-a></a>No causative therapy available, symptomatic treatment</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1452 class=n-a></a>Lowering of persistent symptoms</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1455 class=n-a></a><a href="#ref-34">34</a></td></tr><tr><a name=d46789e1460 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1462 class=n-a></a>Hepatitis C virus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1465 class=n-a></a>Direct-acting antivirals</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1468 class=n-a></a>Sustained virologic responses (= cure)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1471 class=n-a></a><a href="#ref-64">64</a></td></tr><tr><a name=d46789e1476 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1478 class=n-a></a>Hepatitis B virus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1481 class=n-a></a>Medication with nucleos(t)ide analogues</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1484 class=n-a></a>Viral suppression (possibly sustained hepatitis B surface<br class=br>antigen clearance or loss, representing functional cure)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1489 class=n-a></a><a href="#ref-65">65</a></td></tr><tr><a name=d46789e1494 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1496 class=n-a></a>Dysbiosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1499 class=n-a></a>Manipulation of the gut microbiota with diet, probiotics, or fecal microbiota<br class=br>transplantation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1504 class=n-a></a>Growth promotion of "healthy" bacteria</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1507 class=n-a></a><a href="#ref-66">66</a></td></tr><tr><a name=d46789e1512 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1514 class=n-a></a>Primary biliary cholangitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1517 class=n-a></a>Medication (ursodeoxycholic acid, obeticholic acid, budesonide, fibric acid<br class=br>derivatives)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1522 class=n-a></a>Substitution of bile acids; cytoprotective effects in<br class=br>hepatocytes and cholangiocytes; regulation of genes<br class=br>involved in bile acid synthesis, secretion, transport,<br class=br>absorption, and detoxification; activation of peroxisome<br class=br>proliferator-activated receptors and downregulation of<br class=br>several pathways leading to bile acid synthesis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1535 class=n-a></a><a href="#ref-67">67</a></td></tr><tr><a name=d46789e1541 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1543 class=n-a></a>Primary sclerosing<br class=br>cholangitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1548 class=n-a></a>Medication (ursodeoxycholic acid); supportive treatment for symptoms;<br class=br>biliary dilatation (with or without stenting); liver transplantation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1553 class=n-a></a>Lowered liver injury, relieving symptoms; reduction of portal<br class=br>hypertension</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1558 class=n-a></a><a href="#ref-68">68</a></td></tr><tr><a name=d46789e1563 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1565 class=n-a></a>Alcohol</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1568 class=n-a></a>Abstinence/withdrawal, medical therapy of alcohol dependence; specific<br class=br>therapy of steatohepatitis; corticosteroids; liver transplantation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1573 class=n-a></a>Restoration of liver architecture</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1576 class=n-a></a><a href="#ref-69">69</a>,<a href="#ref-70">70</a></td></tr><tr><a name=d46789e1584 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1586 class=n-a></a>Drugs, toxins, and metals</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1589 class=n-a></a>Avoidance/abstinence/dose adjustment/withdrawal</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1592 class=n-a></a>Restoration of liver architecture</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1595 class=n-a></a><a href="#ref-71">71</a></td></tr><tr><a name=d46789e1600 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1602 class=n-a></a>Autoimmune attack</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1605 class=n-a></a>Immunosuppressive treatment regimens (steroids, azathioprine, others);<br class=br>liver transplant</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1610 class=n-a></a>Lowering parenchymal destruction</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1613 class=n-a></a><a href="#ref-72">72</a></td></tr><tr><a name=d46789e1618 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1620 class=n-a></a>Nutrition and metabolic<br class=br>diseases</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1625 class=n-a></a>Lifestyle modifications, mediation with insulin sensitizer agents, lipid-<br class=br>lowering drugs, antioxidants (vitamin E), statins</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1630 class=n-a></a>Lowering of fat uptake and cholesterol levels, normalization<br class=br>of blood glucose; lowering of oxidative stress</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1635 class=n-a></a><a href="#ref-73">73</a></td></tr><tr><a name=d46789e1640 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1642 class=n-a></a>Venous obstruction</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1645 class=n-a></a>Anticoagulation (low-molecular-weight heparin), correction of risk factors,<br class=br>diuretics, prophylaxis for portal hypertension, angioplasty for short-length<br class=br>venous stenosis, transjugular intrahepatic portosystemic shunt, liver<br class=br>transplantation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1654 class=n-a></a>Prevention of thrombosis and portal pressure</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1657 class=n-a></a><a href="#ref-74">74</a></td></tr><tr><a name=d46789e1663 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1665 class=n-a></a>Parasites</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1668 class=n-a></a>Parasite-specific medication (e.g. praziquantel for all <i>Schistosoma</i> species)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1674 class=n-a></a>Ensuring rapid and complete cure of infection and thus<br class=br>preventing the progression of hepatic disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1679 class=n-a></a><a href="#ref-75">75</a></td></tr><tr><a name=d46789e1684 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1686 class=n-a></a>Cryptogenic and<br class=br>congenital liver disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1691 class=n-a></a>No specific therapy available, prevention of alcohol, obesity, diabetes<br class=br>mellitus, malnutrition, immunosuppressive agents, hepatotoxic medicines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1696 class=n-a></a>Prevention of fibrosis progression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d46789e1699 class=n-a></a><a href="#ref-34">34</a></td></tr></tbody></table></div><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16154/91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure3.gif"><img alt="91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16154/91fd1a39-302c-4cc5-8872-5e7e03e46f24_figure3.gif"></a><div class=caption><h3>Figure 3. Strategies to induce resolution of hepatic fibrosis.</h3><p id=d46789e1717>Ongoing hepatic fibrosis can be haltered or resolved by specific therapies, eradication or dietary restriction of the pathogenic cause, or lifestyle and dietary interventions. In addition, several neglected features of lifestyle such as physical exercise, sun exposure, vitamin supplementation, and improved sleep duration and rhythm have been shown to be beneficial in the management of hepatic fibrosis. For more detailed explanations, see text. ACC, acetyl-CoA carboxylase; ACE, angiotensin-converting enzyme; ALD, alcoholic liver disease; ASK1, apoptosis signal-regulating kinase 1; CCL2, C-C motif chemokine ligand 2; CCR2/CCR5, C-C motif chemokine receptor 2/5; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; LOXL2, lysyl oxidase-like 2; NASH, non-alcoholic steatohepatitis; PPAR, peroxisome proliferator-activated receptor; TGR5, G-protein-coupled membrane receptor 5; THR-, thyroid hormone receptor-; TIPS, transjugular intrahepatic portosystemic shunt.</p></div></div><div class=section><a name=d46789e1724 class=n-a></a><h3 class=section-title>Antioxidants</h3><p class="" id=d46789e1729>Oxidative stress and ROS are key drivers of hepatic inflammation and fibrosis. These are formed in the presence of elevated intracellular metal concentrations and also by the specific upregulation of different NADPH oxidases (NOXs) during liver fibrogenesis<sup><a href="#ref-6">6</a>,<a href="#ref-43">43</a></sup>. Therefore, there is great enthusiasm that antioxidants and radical scavengers targeting ROS are beneficial in the therapy of liver disease. Actually, some sulfur-containing and some non-sulfur-containing antioxidants have shown therapeutic effects in many experimental models of hepatic fibrosis<sup><a href="#ref-43">43</a></sup>. In addition, herbal ingredients (e.g. resveratrol, caffeine, and xanthohumol) and medicinal formulations and remedies originating from Traditional Chinese Medicine (TCM) such as <i>Sho-saiko-to</i> and <i>Salvia miltiorrhiza</i> have become the focus of global interest because these substances showed high anti-fibrotic capacity <i>in vitro</i> and in preclinical studies<sup><a href="#ref-43">43</a></sup>. Likewise, the herbal extract silymarin isolated from milk thistle containing the four main components silibinin, silidianin, silicristin, and isosilibinin has been suggested as an effective drug in experimental models that protects against major ROS and prevents mitochondrial failure and inflammation<sup><a href="#ref-43">43</a></sup>. In a randomized, placebo-controlled, multi-center prospective trial with 247 patients, high doses of the antioxidant vitamin E improved histological features of NASH over placebo but did not significantly reduce fibrosis<sup><a href="#ref-76">76</a></sup>. Thus, solid data on the clinical efficacy of antioxidants against fibrosis in humans are still limited.</p></div><div class=section><a name=d46789e1767 class=n-a></a><h3 class=section-title>Inhibition of hepatic damage</h3><p class="" id=d46789e1772>In principle, anti-fibrotic drugs can mediate their effects on three different levels. A fibropreventive drug reduces liver cell damage by protecting hepatocytes from damage and enhancing the elimination of the noxious agent. Fibrostatic drugs suppress the production of new matrix by interfering with or blocking HSC activation or transdifferentiation. The last class consisting of fibrolytic drugs induces resolution of fibrosis by triggering necrosis and apoptosis of MFBs. Based on the complexity of hepatic fibrosis, the theoretical possibilities for therapeutic targeting are quite heterogeneous. Prevention of injury-mediated apoptosis/necrosis with the use of apoptosis blockers is an option addressing fibrosis initiation. Prototypically, the caspase inhibitor IDN-6556 (emricasan) was experimentally effective in protecting mice from cholestatic liver damage, inflammation, and hepatic fibrosis in mice<sup><a href="#ref-77">77</a></sup>. Likewise, the semi-synthetic bile acid obeticholic acid (OCA, INT-747) has anticholestatic and hepatoprotective properties, increases insulin sensitivity, modulates fat metabolism, and exerts anti-inflammatory and anti-fibrotic properties<sup><a href="#ref-78">78</a></sup>. Both agents are currently under clinical evaluation, and OCA has significantly reduced fibrosis in a clinical trial on patients with NASH<sup><a href="#ref-79">79</a></sup>. OCAs and similar drugs from this class target bile acid receptors like the FXR. Best known are endogenous (e.g. chenodeoxycholic acid, deoxycholic acid, cholic acid, and lithocholic acid) and (semi-)synthetic FXR agonists (OCA). In general, these components improve glucose metabolism, enhance insulin sensitivity, reduce hepatic lipogenesis, and increase -oxidation<sup><a href="#ref-4">4</a>,<a href="#ref-43">43</a></sup>. Approved drugs that reduce intestinal cholesterol absorption, increase bile flow, change the hydrophobicity index of the bile acid pool, and provoke anti-inflammatory effects such as the steroid bile acid ursodeoxycholic acid (UDCA) or its side chain-shortened homologue norUDCA that has an increased cholehepatic shunting are also potential therapeutic alternatives<sup><a href="#ref-80">80</a></sup>.</p></div><div class=section><a name=d46789e1799 class=n-a></a><h3 class=section-title>Targeting inflammation</h3><p class="" id=d46789e1804>Another therapeutic starting point is to target inflammatory mediators or to inhibit inflammatory monocyte infiltration. Neutralization of osteopontin becoming highly upregulated in fibrotic tissues, thereby increasing activity of TGF- and chemoattraction of macrophages, was sufficient to abrogate fibrogenesis in mouse models of liver fibrosis by influencing liver progenitor cell function<sup><a href="#ref-81">81</a></sup>. Direct targeting of chemokines involved in the production of an inflammatory environment was also shown to arrest ongoing hepatic fibrogenesis<sup><a href="#ref-82">82</a></sup>. Prototypically, this was demonstrated by the application of an RNA-L-aptamer-based inhibitor (NOX-E36) targeting the CCL2/CCR2 axis. NOX-E36 is a synthetic 40mer mirror-image RNA L-aptamer (Spiegelmer), which potently binds to its pharmacologically relevant target molecule (i.e. CCL2) in a manner conceptually similar to an antibody and inhibits its biological activity. This drug prevented the attraction of inflammatory monocytes into the injured liver and ameliorated hepatic steatosis in murine models of acute and chronic hepatic injury<sup><a href="#ref-83">83</a></sup>. Likewise, transgenic overexpression or application of IL-22 induced HSC senescence, thereby reducing liver fibrosis, most likely by pathways involving STAT3, p53, and p21<sup><a href="#ref-84">84</a></sup>. Encouraging pilot studies have shown that the serum amyloid P component (SAP) and other classical plasma pentraxin proteins bind directly to monocytes, neutrophils, and macrophages, thereby modifying their activation, spreading, and polarization and inhibiting their differentiation into fibrocytes<sup><a href="#ref-85">85</a>,<a href="#ref-86">86</a></sup>. It is obvious that these findings will trigger future studies aiming to investigate the beneficial effects of pentraxins in the attenuation of hepatic inflammation and fibrosis.</p></div><div class=section><a name=d46789e1831 class=n-a></a><h3 class=section-title>Deactivation and elimination of extracellular matrix-producing cells</h3><p class="" id=d46789e1836>A main challenge in the attenuation of hepatic fibrosis is the lowering of cellular amount and activity of matrix-producing cells in the injured tissue. Targeted induction of apoptosis and senescence or the deactivation of the respective cell pool is experimentally achieved in many ways. Expression of proteins acting as a trigger of cellular senescence was capable of reducing the production of collagen type I at both mRNA and protein levels in HSCs and portal MFBs through the induction of ROS and attenuated TGF- signaling<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>. Also, modulating the inflammatory environment can induce deactivation of matrix-producing MFBs<sup><a href="#ref-89">89</a></sup>.</p></div><div class=section><a name=d46789e1851 class=n-a></a><h3 class=section-title>Inhibitors of cytokine signaling</h3><p class="" id=d46789e1856>There are numerous approaches demonstrating the efficacy of biological sequestering of pro-fibrogenic cytokines acting in an autocrine or paracrine manner. In particular, prominent anti-fibrotic effects were reported when targeting the TGF- axis with its receptors and intracellular signaling mediators, the Smad proteins. Based on the complexity of TGF- and its different signaling branches, the therapeutic targets are manifold. In experimental studies, soluble receptors biologically sequestering active TGF-, dominant-negative TGF- receptors, antisense strategies interfering with the synthesis of TGF-, the expression of inhibitory Smad proteins, and the application of novel small inhibitors blocking the activity of individual receptors were successfully tested in preclinical models<sup><a href="#ref-43">43</a></sup>. Correspondingly, numerous investigations have demonstrated the applicability of anti-fibrotic strategies when targeting the platelet-derived growth factor (PDGF) family and its signaling compounds<sup><a href="#ref-90">90</a></sup>. This cytokine family has important roles in HSC and portal MFB proliferation, chemotaxis, migration, and cell survival. Respective therapeutic drugs (e.g. multikinase inhibitors and aptamers) targeting PDGF signaling are explored in advanced preclinical studies. Also, some cytokines developing inflammatory activity (TNF- and interleukins) and apoptotic features (NGF), increasing portal pressure (VEGF), promoting fibrosis (FGF), or having immunomodulatory activity (IFN) or other pleiotropic activities influencing hepatic fibrogenesis (HGF and IGF) are under thorough investigation. However, although the list of potential anti-fibrotic drugs is rapidly increasing, most of these drugs have so far been tested only in experimental models of hepatic fibrosis and wait to be translated into clinical trials<sup><a href="#ref-43">43</a></sup>.</p></div><div class=section><a name=d46789e1872 class=n-a></a><h3 class=section-title>Production and degradation of extracellular matrix</h3><p class="" id=d46789e1877>Fundamental work has shown that a balance between matrix metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) is of fundamental importance in the homeostasis of extracellular matrix content within the liver<sup><a href="#ref-91">91</a></sup>. Moreover, the distinct expression and activity of individual MMPs and TIMPs are necessary to guarantee fibrolysis during the resolution of liver fibrosis<sup><a href="#ref-92">92</a></sup>. This knowledge will hopefully lead to the identification of novel therapeutic drug targets. Similarly, the lysyl oxidase-like 2 (LOXL2) belonging to a family of five proteins involved in collagen crosslinking and stabilization is key in promoting liver fibrosis and limiting its resolution. In line with this functionality, it was demonstrated that early treatment with the inhibitory monoclonal LOXL2 antibody AB0023 was effective in a mouse model of mild liver fibrosis by reducing the number of activated fibroblasts and decreasing the production of growth factors and cytokines<sup><a href="#ref-93">93</a></sup>. In a more recent study, this antibody was also shown to be effective in advanced, pre-established biliary and non-biliary fibrosis and in promoting the reversal of advanced parenchymal liver fibrosis in mice<sup><a href="#ref-94">94</a></sup>. Although these encouraging studies suggest that targeted LOXL2 inhibition is an attractive therapeutic option in fibrosis prevention or regression, clinical trials with the anti-LOXL2 antibody simtuzumab showed no anti-fibrotic activity in patients with hepatic fibrosis<sup><a href="#ref-46">46</a></sup>.</p></div><div class=section><a name=d46789e1901 class=n-a></a><h3 class=section-title>Viral eradication, removal of parasites, and drug/toxin withdrawal</h3><p class="" id=d46789e1906>Numerous studies have confirmed that the simple withdrawal or suppression of the injurious stimulus can lead to the spontaneous resolution of fibrosis with a restoration to normal liver architecture<sup><a href="#ref-95">95</a></sup>. All these studies demonstrate that liver fibrosis is a dynamic bidirectional process, allowing regression and recovery even when fibrosis is advanced<sup><a href="#ref-96">96</a></sup>. Therefore, it is evident that the elimination or reduction of viral load in chronic viral hepatitis by anti-viral drugs (or combinations), the removal of hepatic parasites, or the withdrawal of any drug or toxin leading to parenchymal damage is still the first option in treating all fibrotic lesions of the liver. In most cases of parasitic infections, adequate medication (e.g. praziquantel for all <i>Schistosoma</i> species) is available.</p></div><div class=section><a name=d46789e1922 class=n-a></a><h3 class=section-title>Restoration of intestinal eubiosis and homeostasis</h3><p class="" id=d46789e1927>The microbial ecosystem of the gastrointestinal tract is composed of a great number of highly varied microbial species. The sum and composition of these microorganisms, i.e. the microbiota, are critically influenced by the hosts genotype and environmental factors such as age, diet, drug use, alcohol intake, stress, and others. Intestinal eubiosis is important to guarantee proper intestinal functions including motility, energy harvest, mucosal immunity, and proper digestion. Modulation of gut microbiota by fecal transplant, also known as stool transplant, from a healthy individual into a recipient suffering from a disease presumed to be caused by alterations or disruption of the microbiota has become increasingly popular. Experimental work has demonstrated that the restoration of a healthy intestinal microbiota is sufficient to normalize portal hypertension in a rat model of NASH<sup><a href="#ref-97">97</a></sup>. Likewise, the manipulation of the intestinal microbiota by fecal microbiota transplantation with fresh feces from alcohol-resistant donor mice to alcohol-sensitive receiver mice prevented alcohol-induced liver injury, steatosis, and liver inflammation and restored gut homeostasis in mice<sup><a href="#ref-98">98</a></sup>. It is therefore conceivable that microbiota manipulation with anti-fibrotic microbes may allow the establishment of novel treatment possibilities in human liver disease.</p></div><div class=section><a name=d46789e1939 class=n-a></a><h3 class=section-title>Restoration of blood flow</h3><p class="" id=d46789e1944>Portal vein thrombosis and venous obstruction are common complications in advanced liver fibrosis and cirrhosis. In patients with a persistent documented prothrombotic state, anticoagulation (e.g. with low-molecular-weight heparin) has been shown to prevent the progression of portal vein obstruction occurring because of thrombosis<sup><a href="#ref-47">47</a></sup>. Experimental models yielded divergent results on whether therapeutic anticoagulation (e.g. enoxaparin) reduces fibrosis and vascular resistance<sup><a href="#ref-99">99</a>,<a href="#ref-100">100</a></sup>. In a prospective randomized trial, enoxaparin prevented portal vein thrombosis, hepatic decompensation, and mortality in patients with advanced liver cirrhosis<sup><a href="#ref-101">101</a></sup>.</p></div><div class=section><a name=d46789e1963 class=n-a></a><h3 class=section-title>Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease</h3><p class="" id=d46789e1968>In the general population, NAFLD is estimated to afflict up to 30% of the general population in the Western countries and is in most cases provoked by physical inactivity and excessive calorie intake<sup><a href="#ref-102">102</a></sup>. In particular, NAFLD occurs in middle-aged subjects in association with obesity, hyperglycemia, dyslipidemia, and type 2 diabetes. The abundant fat tissue in visceral obesity is linked to enhanced secretion of pro-inflammatory adipokines including TNF, leptin, IL-6 and IL-18, RBP-4, CCL2, CXCL5, lipocalin 2 (LCN2), and ANGPTL2<sup><a href="#ref-103">103</a></sup>. Therefore, the risk of NAFLD, NASH, diabetes, and associated metabolic syndrome could be principally prevented by lifestyle changes (healthy diet, weight loss, and regular physical exercise) that have direct consequences on inflammatory signaling pathways triggered by excess free fatty acids in obesity<sup><a href="#ref-104">104</a></sup>. However, the great wealth of tempting high-fat and high-sugar food propagated by industry and the hectic and stressful nature of today's Western world often hamper these adjustments. Therefore, several supportive pharmaceuticals are under close investigation. A recent meta-analysis of eight randomized clinical trials enrolling 516 patients with biopsy-proven NASH revealed that thiazolidinedione therapy (rosiglitazone or pioglitazone) was associated with improved fibrosis and NASH resolution, even in patients without diabetes<sup><a href="#ref-105">105</a></sup>. Other clinical candidate drugs for NASH are agonists for the FXR such as OCA (INT-747) or for the glucagon-like peptide-1 receptor (GLP-1R). Based on the beneficial effect of OCA, this compound is being tested presently (in phase 2 and phase 3 clinical studies) as a possible treatment for NASH, NAFLD, obesity, alcoholic hepatitis, and other liver and gastrointestinal conditions. The stimulation of FXR involved in the regulation of genes associated with bile acid synthesis and lipoprotein metabolism with the agonist WAY-362450 (turofexorate isopropyl, XL335, FXR-450) protected against hepatic inflammation and fibrosis in a murine model of NASH<sup><a href="#ref-106">106</a></sup>. In similar experimental studies in mice, GLP-1R agonists reduced body weight, liver mass, liver lipid, plasma alanine aminotransferase, and triglycerides<sup><a href="#ref-107">107</a></sup>. More recent findings suggested FXR and GLP-1 co-activation to be more therapeutically beneficial<sup><a href="#ref-108">108</a></sup>. Another NAFLD/NASH treatment option is the supplementation with vitamin E, which has shown beneficial effects on serum liver enzymes, steatosis, inflammation, hepatocellular ballooning, and hepatic fibrosis<sup><a href="#ref-109">109</a></sup>. In addition to these drugs, several anti-inflammatory drugs are under consideration. The apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib (GS-4997) has demonstrated reduced liver fibrosis, liver stiffness, and lobular inflammation in NASH patients and subjects with stage 23 fibrosis<sup><a href="#ref-110">110</a></sup>. Moreover, the PPAR/d agonist elafibranor improved inflammation and fibrosis in mouse models of NAFLD and has now entered phase 3 clinical trials<sup><a href="#ref-111">111</a></sup>. Similar to its therapeutic effects in experimental studies<sup><a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup>, the C-C motif chemokine receptor 2/5 (CCR2/5) antagonist cenicriviroc (CVC) improved hepatic fibrosis and systemic inflammation in NASH patients<sup><a href="#ref-114">114</a></sup>. To sum up, there is a large list of compounds currently being evaluated in advanced clinical trials for the treatment of NASH and NAFLD. It is suggested that the availability of therapeutic options for NASH will curb the rising trend of respective diseases<sup><a href="#ref-111">111</a></sup>. Currently, other pharmacotherapeutics for NAFLD and NASH such as GR-MD-02, which binds to the carbohydrate-binding domain of galectin-3, which is upregulated in cases of liver fibrosis and has an essential function in cellcell interactions, angiogenesis, apoptosis, and macrophage activation, are also under investigation<sup><a href="#ref-115">115</a></sup>. Beside these pharmaceutical treatment options, weight loss induced by lifestyle changes and controlled exercise have outstanding value in the treatment of fatty liver disease<sup><a href="#ref-102">102</a></sup>. This was impressively demonstrated in a prospective study of 293 patients with histologically proven NASH, in which effective lifestyle changes to reduce weight over 52 weeks improved histologic features associated with NASH<sup><a href="#ref-116">116</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d46789e2044>Conclusions</h2><p class="" id=d46789e2047>There is a large variety of factors, including genetic disorders, chronic viral infection, alcohol abuse, autoimmune attacks, metabolic disorder, cholestasis, venous obstruction, and parasite infection, that cause hepatic fibrosis. Although the molecular and cellular processes leading to fibrosis are more or less the same, the different etiologies require different treatments. Sound clinical practice guidelines and recommendations were established for almost any disease constellation. Beside standardized medication and individualized interventional strategies, many experimental studies are currently being conducted to test drugs that inhibit liver damage, target inflammation, reduce the number or activation state of matrix-producing cells, or inhibit the biological activity of pro-fibrotic soluble mediators (cytokines and chemokines). In particular, novel promising NASH and NAFLD drugs (GLP-1R antagonists, pioglitazone, vitamin E, elafibranor, OCA, selonsertib, simtuzumab, GR-MD-02, and CVC) from the pipeline of the pharmaceutical industry are being tested in advanced clinical trials and possibly will be approved as medications in the near future. However, in the case of NAFLD and NASH, lifestyle modification including specialized diets and physical activity leading to weight reduction, reduced liver fat, and improved glucose balance is still an effective option to improve liver overall health.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d46789e2053>Abbreviations</h2><p class="" id=d46789e2056>ABC, ATP-binding cassette; AIH, autoimmune hepatitis; CVC, cenicriviroc; DILI, drug-induced liver injury; GLP-1, glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1 receptor; HCC, hepatocellular carcinoma; HSC, hepatic stellate cell; LOXL2, lysyl oxidase-like 2; MFB, myofibroblast; MMP, matrix metalloproteinase; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PDGF, platelet-derived growth factor; PSC, primary sclerosing cholangitis; ROS, reactive oxygen species; TGF-, transforming growth factor-; TIMP, tissue inhibitors of metalloproteinase.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d46789e1 class=n-a></a><h2 class=main-title id=d47101>Competing interests</h2><p class=metadata-entry><a name=d46789e111 class=n-a></a><p id=d46789e112> Work in the laboratory of Frank Tacke has been supported by funding from Tobira Therapeutics, Bristol Myers Squibb, and Galapagos. Ralf Weiskirchen cooperates with Silence Therapeutics.</p></p></div><div class=back-section><a name=d46789e1 class=n-a></a><h2 class=main-title id=d47103>Grant information</h2><p>This work was supported by the German Research Foundation (DFG, SFB/TRR57) and grants from the Interdisciplinary Centre for Clinical Research (projects O3-1, O3-2) within the Faculty of Medicine at the RWTH Aachen University.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d46789e2062 class=n-a></a><h2 class=main-title id=d46789e2064>Acknowledgements</h2><p class="" id=d46789e2067>We cordially thank all members of our labs and collaborating scientists for helpful discussions.</p></div><div class=back-section><a name=d46789e2071 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d47491>References</h2><div class="section ref-list"><a name=d46789e2071 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d46789e2078 class=n-a></a>Weiskirchen R, Tacke F: Liver Fibrosis: From Pathogenesis to Novel Therapies. <i>Dig Dis.</i> 2016; <b>34</b>(4): 41022. <a target=xrefwindow id=d46789e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/27170396">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2089 href="http://dx.doi.org/10.1159/000444556">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d46789e2098 class=n-a></a>Weiskirchen R, Weiskirchen S, Tacke F: Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications.<i> Mol Aspects Med.</i> In press. <a target=xrefwindow id=d46789e2103 href="http://dx.doi.org/10.1016/j.mam.2018.06.003">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d46789e2112 class=n-a></a>Marra F, Svegliati-Baroni G: Lipotoxicity and the gut-liver axis in NASH pathogenesis. <i>J Hepatol.</i> 2018; <b>68</b>(2): 28095. <a target=xrefwindow id=d46789e2120 href="http://www.ncbi.nlm.nih.gov/pubmed/29154964">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2123 href="http://dx.doi.org/10.1016/j.jhep.2017.11.014">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d46789e2132 class=n-a></a>Cruz-Ramn V, Chinchilla-Lpez P, Ramrez-Prez O, <i> et al.</i>: Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances. <i>Ann Hepatol.</i> 2017; <b>16</b>(Suppl. 1: s3105): s58s67. <a target=xrefwindow id=d46789e2143 href="http://www.ncbi.nlm.nih.gov/pubmed/29080343">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2146 href="http://dx.doi.org/10.5604/01.3001.0010.5498">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d46789e2155 class=n-a></a>Ramrez-Prez O, Cruz-Ramn V, Chinchilla-Lpez P, <i> et al.</i>: The Role of the Gut Microbiota in Bile Acid Metabolism. <i>Ann Hepatol.</i> 2017; <b>16</b>(Suppl. 1: s3105): s15s20. <a target=xrefwindow id=d46789e2166 href="http://www.ncbi.nlm.nih.gov/pubmed/29080339">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2169 href="http://dx.doi.org/10.5604/01.3001.0010.5494">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d46789e2179 class=n-a></a>Susnea I, Weiskirchen R: Trace metal imaging in diagnostic of hepatic metal disease. <i>Mass Spectrom Rev.</i> 2016; <b>35</b>(6): 66686. <a target=xrefwindow id=d46789e2187 href="http://www.ncbi.nlm.nih.gov/pubmed/25677057">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2190 href="http://dx.doi.org/10.1002/mas.21454">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732813318"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2199 class=n-a></a>Gerhard GS, Paynton BV, DiStefano JK: Identification of Genes for Hereditary Hemochromatosis. <i>Methods Mol Biol.</i> 2018; <b>1706</b>: 35365. <a target=xrefwindow id=d46789e2207 href="http://www.ncbi.nlm.nih.gov/pubmed/29423808">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2210 href="http://dx.doi.org/10.1007/978-1-4939-7471-9_19">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732813318">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d46789e2223 class=n-a></a>Ranucci G, Polishchuck R, Iorio R: Wilson's disease: Prospective developments towards new therapies. <i>World J Gastroenterol.</i> 2017; <b>23</b>(30): 54516. <a target=xrefwindow id=d46789e2231 href="http://www.ncbi.nlm.nih.gov/pubmed/28852304">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2234 href="http://dx.doi.org/10.3748/wjg.v23.i30.5451">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2237 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5558108">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d46789e2246 class=n-a></a>Yoo EG: Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management. <i>Ann Pediatr Endocrinol Metab.</i> 2016; <b>21</b>(1): 714. <a target=xrefwindow id=d46789e2254 href="http://www.ncbi.nlm.nih.gov/pubmed/27104173">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2257 href="http://dx.doi.org/10.6065/apem.2016.21.1.7">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2260 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4835564">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d46789e2269 class=n-a></a>Chinsky JM, Singh R, Ficicioglu C, <i> et al.</i>: Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. <i>Genet Med.</i> 2017; <b>19</b>(12). <a target=xrefwindow id=d46789e2280 href="http://www.ncbi.nlm.nih.gov/pubmed/28771246">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2283 href="http://dx.doi.org/10.1038/gim.2017.101">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5729346">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d46789e2296 class=n-a></a>Summar ML, Mew NA: Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders. <i>Pediatr Clin North Am.</i> 2018; <b>65</b>(2): 23146. <a target=xrefwindow id=d46789e2304 href="http://www.ncbi.nlm.nih.gov/pubmed/29502911">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2307 href="http://dx.doi.org/10.1016/j.pcl.2017.11.004">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d46789e2317 class=n-a></a>Demirbas D, Brucker WJ, Berry GT: Inborn Errors of Metabolism with Hepatopathy: Metabolism Defects of Galactose, Fructose, and Tyrosine. <i>Pediatr Clin North Am.</i> 2018; <b>65</b>(2): 33752. <a target=xrefwindow id=d46789e2325 href="http://www.ncbi.nlm.nih.gov/pubmed/29502917">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2328 href="http://dx.doi.org/10.1016/j.pcl.2017.11.008">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d46789e2337 class=n-a></a>Perlmutter DH, Silverman GA: Hepatic fibrosis and carcinogenesis in 1-antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders. <i>Cold Spring Harb Perspect Biol.</i> 2011; <b>3</b>(3): pii: a005801. <a target=xrefwindow id=d46789e2345 href="http://www.ncbi.nlm.nih.gov/pubmed/21421920">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2348 href="http://dx.doi.org/10.1101/cshperspect.a005801">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2351 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3039936">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732434987"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2360 class=n-a></a>Mitchell EL, Khan Z: Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions. <i>Curr Pathobiol Rep.</i> 2017; <b>5</b>(3): 24352. <a target=xrefwindow id=d46789e2368 href="http://www.ncbi.nlm.nih.gov/pubmed/29399420">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2371 href="http://dx.doi.org/10.1007/s40139-017-0147-5">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2374 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5780543">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732434987">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d46789e2387 class=n-a></a>Weiskirchen R, Meurer SK: BMP-7 counteracting TGF-beta1 activities in organ fibrosis. <i>Front Biosci (Landmark Ed).</i> 2013; <b>18</b>: 140734. <a target=xrefwindow id=d46789e2395 href="http://www.ncbi.nlm.nih.gov/pubmed/23747893">PubMed Abstract </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d46789e2404 class=n-a></a>McDaniell R, Warthen DM, Sanchez-Lara PA, <i> et al.</i>: <i>NOTCH2</i> mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. <i>Am J Hum Genet.</i> 2006; <b>79</b>(1): 16973. <a target=xrefwindow id=d46789e2418 href="http://www.ncbi.nlm.nih.gov/pubmed/16773578">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2422 href="http://dx.doi.org/10.1086/505332">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2425 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1474136">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727225035"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2434 class=n-a></a>Pollock G, Minuk GY: Diagnostic considerations for cholestatic liver disease. <i>J Gastroenterol Hepatol.</i> 2017; <b>32</b>(7): 13039. <a target=xrefwindow id=d46789e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/28106928">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2445 href="http://dx.doi.org/10.1111/jgh.13738">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727225035">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d46789e2459 class=n-a></a>Woolbright BL, Jaeschke H: Alcoholic Hepatitis: Lost in Translation. <i>J Clin Transl Hepatol.</i> 2018; <b>6</b>(1): 8996. <a target=xrefwindow id=d46789e2467 href="http://www.ncbi.nlm.nih.gov/pubmed/29577035">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2470 href="http://dx.doi.org/10.14218/JCTH.2017.00054">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2473 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5863004">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d46789e2482 class=n-a></a>Purohit V, Brenner DA: Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. <i>Hepatology.</i> 2006; <b>43</b>(4): 8728. <a target=xrefwindow id=d46789e2490 href="http://www.ncbi.nlm.nih.gov/pubmed/16502397">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2493 href="http://dx.doi.org/10.1002/hep.21107">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727871317"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2502 class=n-a></a>Kawaratani H, Moriya K, Namisaki T, <i> et al.</i>: Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review). <i>Int J Mol Med.</i> 2017; <b>40</b>(2): 26370. <a target=xrefwindow id=d46789e2513 href="http://www.ncbi.nlm.nih.gov/pubmed/28627645">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2516 href="http://dx.doi.org/10.3892/ijmm.2017.3015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727871317">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726493164"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2529 class=n-a></a>Stanaway JD, Flaxman AD, Naghavi M, <i> et al.</i>: The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. <i>Lancet.</i> 2016; <b>388</b>(10049): 10818. <a target=xrefwindow id=d46789e2540 href="http://www.ncbi.nlm.nih.gov/pubmed/27394647">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2543 href="http://dx.doi.org/10.1016/S0140-6736(16)30579-7">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2547 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5100695">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726493164">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731120157"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2560 class=n-a></a>Ringelhan M, McKeating JA, Protzer U: Viral hepatitis and liver cancer. <i>Philos Trans R Soc Lond B Biol Sci.</i> 2017; <b>372</b>(1732): pii: 20160274. <a target=xrefwindow id=d46789e2568 href="http://www.ncbi.nlm.nih.gov/pubmed/28893941">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2571 href="http://dx.doi.org/10.1098/rstb.2016.0274">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5597741">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731120157">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733487723"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2587 class=n-a></a>Petruzziello A: Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. <i>Open Virol J.</i> 2018; <b>12</b>: 2632. <a target=xrefwindow id=d46789e2595 href="http://www.ncbi.nlm.nih.gov/pubmed/29541276">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2598 href="http://dx.doi.org/10.2174/1874357901812010026">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2601 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5842386">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733487723">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d46789e2615 class=n-a></a>Perz JF, Armstrong GL, Farrington LA, <i> et al.</i>: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. <i>J Hepatol.</i> 2006; <b>45</b>(4): 52938. <a target=xrefwindow id=d46789e2626 href="http://www.ncbi.nlm.nih.gov/pubmed/16879891">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2629 href="http://dx.doi.org/10.1016/j.jhep.2006.05.013">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732962791"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2638 class=n-a></a>Polaris Observatory Collaborators: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>Lancet Gastroenterol Hepatol.</i> 2018; <b>3</b>(6): 383403. <a target=xrefwindow id=d46789e2646 href="http://www.ncbi.nlm.nih.gov/pubmed/29599078">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2649 href="http://dx.doi.org/10.1016/S2468-1253(18)30056-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732962791">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d46789e2662 class=n-a></a>Papatheodoridis GV, Hatzakis A, Cholongitas E, <i> et al.</i>: Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. <i>J Viral Hepat.</i> 2018; <b>25 Suppl 1</b>: 617. <a target=xrefwindow id=d46789e2673 href="http://www.ncbi.nlm.nih.gov/pubmed/29508946">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2676 href="http://dx.doi.org/10.1111/jvh.12875">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d46789e2685 class=n-a></a>Devarbhavi H: An Update on Drug-induced Liver Injury. <i>J Clin Exp Hepatol.</i> 2012; <b>2</b>(3): 24759. <a target=xrefwindow id=d46789e2693 href="http://www.ncbi.nlm.nih.gov/pubmed/25755441">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2696 href="http://dx.doi.org/10.1016/j.jceh.2012.05.002">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2699 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3940315">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d46789e2708 class=n-a></a>Srivastava A: Progressive familial intrahepatic cholestasis. <i>J Clin Exp Hepatol.</i> 2014; <b>4</b>(1): 2536. <a target=xrefwindow id=d46789e2716 href="http://www.ncbi.nlm.nih.gov/pubmed/25755532">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2719 href="http://dx.doi.org/10.1016/j.jceh.2013.10.005">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2722 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4017198">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d46789e2731 class=n-a></a>Saheki T, Song YZ: Citrin Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews<sup></sup> [Internet]. Seattle (WA): University of Washington, Seattle; 19932018. 2005; [updated 2017 Aug 10]. <a target=xrefwindow id=d46789e2736 href="http://www.ncbi.nlm.nih.gov/pubmed/20301360">PubMed Abstract </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d46789e2746 class=n-a></a>Zhang H: Lysosomal acid lipase and lipid metabolism: new mechanisms, new questions, and new therapies. <i>Curr Opin Lipidol.</i> 2018; <b>29</b>(3): 21823. <a target=xrefwindow id=d46789e2754 href="http://www.ncbi.nlm.nih.gov/pubmed/29547398">PubMed Abstract </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732895908"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2763 class=n-a></a>Turner AM, Stolk J, Bals R, <i> et al.</i>: Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. <i>J Hepatol.</i> 2018; pii: S0168-8278(18)30176-4. <a target=xrefwindow id=d46789e2771 href="http://www.ncbi.nlm.nih.gov/pubmed/29572094">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2774 href="http://dx.doi.org/10.1016/j.jhep.2018.03.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732895908">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d46789e2787 class=n-a></a>Kamal N, Surana P, Koh C: Liver disease in patients with cystic fibrosis. <i>Curr Opin Gastroenterol.</i> 2018; <b>34</b>(3): 14651. <a target=xrefwindow id=d46789e2795 href="http://www.ncbi.nlm.nih.gov/pubmed/29438119">PubMed Abstract </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d46789e2804 class=n-a></a>lvarez-Satta M, Castro-Snchez S, Valverde D: Alstrm syndrome: current perspectives. <i>Appl Clin Genet.</i> 2015; <b>8</b>: 1719. <a target=xrefwindow id=d46789e2812 href="http://www.ncbi.nlm.nih.gov/pubmed/26229500">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2815 href="http://dx.doi.org/10.2147/TACG.S56612">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2818 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4516341">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d46789e2827 class=n-a></a>Gunay-Aygun M, Gahl WA, Heller T: Congenital Hepatic Fibrosis Overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews<sup></sup> [Internet]. Seattle (WA): University of Washington, Seattle; 19932018. 2008 [updated 2014 Apr 24]. <a target=xrefwindow id=d46789e2832 href="http://www.ncbi.nlm.nih.gov/pubmed/20301743">PubMed Abstract </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732801202"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2841 class=n-a></a>Christen U, Hintermann E: Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease? <i>Front Immunol.</i> 2018; <b>9</b>: 163. <a target=xrefwindow id=d46789e2849 href="http://www.ncbi.nlm.nih.gov/pubmed/29503645">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2852 href="http://dx.doi.org/10.3389/fimmu.2018.00163">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2855 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5820307">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732801202">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d46789e2869 class=n-a></a>Yamagiwa S, Kamimura H, Takamura M, <i> et al.</i>: Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. <i>World J Gastroenterol.</i> 2014; <b>20</b>(10): 260612. <a target=xrefwindow id=d46789e2880 href="http://www.ncbi.nlm.nih.gov/pubmed/24627596">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2883 href="http://dx.doi.org/10.3748/wjg.v20.i10.2606">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2887 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3949269">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732278095"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2896 class=n-a></a>Toh BH: Diagnostic autoantibodies for autoimmune liver diseases. <i>Clin Transl Immunology.</i> 2017; <b>6</b>(5): e139. <a target=xrefwindow id=d46789e2904 href="http://www.ncbi.nlm.nih.gov/pubmed/28690845">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2907 href="http://dx.doi.org/10.1038/cti.2017.14">Publisher Full Text </a> | <a target=xrefwindow id=d46789e2910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5493583">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732278095">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728639860"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2923 class=n-a></a>Karlsen TH, Folseraas T, Thorburn D, <i> et al.</i>: Primary sclerosing cholangitis - a comprehensive review. <i>J Hepatol.</i> 2017; <b>67</b>(6): 1298323. <a target=xrefwindow id=d46789e2934 href="http://www.ncbi.nlm.nih.gov/pubmed/28802875">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2937 href="http://dx.doi.org/10.1016/j.jhep.2017.07.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728639860">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d46789e2950 class=n-a></a>Bunchorntavakul C, Reddy KR: Diagnosis and management of overlap syndromes. <i>Clin Liver Dis.</i> 2015; <b>19</b>(1): 8197. <a target=xrefwindow id=d46789e2958 href="http://www.ncbi.nlm.nih.gov/pubmed/25454298">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2961 href="http://dx.doi.org/10.1016/j.cld.2014.09.005">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732679390"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e2970 class=n-a></a>Arab JP, Arrese M, Trauner M: Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Annu Rev Pathol.</i> 2018; <b>13</b>: 32150. <a target=xrefwindow id=d46789e2978 href="http://www.ncbi.nlm.nih.gov/pubmed/29414249">PubMed Abstract </a> | <a target=xrefwindow id=d46789e2981 href="http://dx.doi.org/10.1146/annurev-pathol-020117-043617">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732679390">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d46789e2994 class=n-a></a>Lambertz J, Weiskirchen S, Landert S, <i> et al.</i>: Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease. <i>Front Immunol.</i> 2017; <b>8</b>: 1159. <a target=xrefwindow id=d46789e3005 href="http://www.ncbi.nlm.nih.gov/pubmed/28970836">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3008 href="http://dx.doi.org/10.3389/fimmu.2017.01159">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3012 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5609573">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732609805"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3022 class=n-a></a>Jensen T, Abdelmalek MF, Sullivan S, <i> et al.</i>: Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. <i>J Hepatol.</i> 2018; <b>68</b>(5): 106375. <a target=xrefwindow id=d46789e3033 href="http://www.ncbi.nlm.nih.gov/pubmed/29408694">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3036 href="http://dx.doi.org/10.1016/j.jhep.2018.01.019">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3040 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5893377">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732609805">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d46789e3053 class=n-a></a>Weiskirchen R: Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. <i>Front Pharmacol.</i> 2016; <b>6</b>: 303. <a target=xrefwindow id=d46789e3061 href="http://www.ncbi.nlm.nih.gov/pubmed/26779021">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3064 href="http://dx.doi.org/10.3389/fphar.2015.00303">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3067 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4703795">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732365625"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3076 class=n-a></a>Bae M, Park YK, Lee JY: Food components with antifibrotic activity and implications in prevention of liver disease. <i>J Nutr Biochem.</i> 2018; <b>55</b>: 111. <a target=xrefwindow id=d46789e3084 href="http://www.ncbi.nlm.nih.gov/pubmed/29268106">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3087 href="http://dx.doi.org/10.1016/j.jnutbio.2017.11.003">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3090 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5936673">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732365625">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727742080"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3103 class=n-a></a>Sanduzzi Zamparelli M, Rocco A, Compare D, <i> et al.</i>: The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. <i>United European Gastroenterol J.</i> 2017; <b>5</b>(7): 94453. <a target=xrefwindow id=d46789e3114 href="http://www.ncbi.nlm.nih.gov/pubmed/29163959">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3117 href="http://dx.doi.org/10.1177/2050640617705576">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3121 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5676553">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727742080">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727572862"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3134 class=n-a></a>Loomba R, Seguritan V, Li W, <i> et al.</i>: Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metab.</i> 2017; <b>25</b>(5): 10541062.e5. <a target=xrefwindow id=d46789e3145 href="http://www.ncbi.nlm.nih.gov/pubmed/28467925">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3148 href="http://dx.doi.org/10.1016/j.cmet.2017.04.001">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3152 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5502730">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727572862">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d46789e3165 class=n-a></a>Kumar A, Sharma P, Arora A: Review article: portal vein obstruction--epidemiology, pathogenesis, natural history, prognosis and treatment. <i>Aliment Pharmacol Ther.</i> 2015; <b>41</b>(3): 27692. <a target=xrefwindow id=d46789e3173 href="http://www.ncbi.nlm.nih.gov/pubmed/25475582">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3176 href="http://dx.doi.org/10.1111/apt.13019">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d46789e3186 class=n-a></a>Bayraktar U, Seren S, Bayraktar Y: Hepatic venous outflow obstruction: three similar syndromes. <i>World J Gastroenterol.</i> 2007; <b>13</b>(13): 191227. <a target=xrefwindow id=d46789e3194 href="http://www.ncbi.nlm.nih.gov/pubmed/17461490">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3197 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4146966">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d46789e3206 class=n-a></a>Anthony B, Allen JT, Li YS, <i> et al.</i>: Hepatic stellate cells and parasite-induced liver fibrosis. <i>Parasit Vectors.</i> 2010; <b>3</b>(1): 60. <a target=xrefwindow id=d46789e3217 href="http://www.ncbi.nlm.nih.gov/pubmed/20663176">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3220 href="http://dx.doi.org/10.1186/1756-3305-3-60">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3224 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2915969">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730617061"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3233 class=n-a></a>Liu Y, Abudounnasier G, Zhang T, <i> et al.</i>: Increased Expression of TGF-1 in Correlation with Liver Fibrosis during <i>Echinococcus granulosus</i> Infection in Mice. <i>Korean J Parasitol.</i> 2016; <b>54</b>(4): 51925. <a target=xrefwindow id=d46789e3247 href="http://www.ncbi.nlm.nih.gov/pubmed/27658605">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3251 href="http://dx.doi.org/10.3347/kjp.2016.54.4.519">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5040079">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730617061">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726370680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3267 class=n-a></a>Zhang C, Wang L, Ali T, <i> et al.</i>: Hydatid cyst fluid promotes peri-cystic fibrosis in cystic echinococcosis by suppressing miR-19 expression. <i>Parasit Vectors.</i> 2016; <b>9</b>(1): 278. <a target=xrefwindow id=d46789e3278 href="http://www.ncbi.nlm.nih.gov/pubmed/27177776">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3281 href="http://dx.doi.org/10.1186/s13071-016-1562-x">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3285 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4866024">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726370680">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d46789e3298 class=n-a></a>Ku NO, Gish R, Wright TL, <i> et al.</i>: Keratin 8 mutations in patients with cryptogenic liver disease. <i>N Engl J Med.</i> 2001; <b>344</b>(21): 15807. <a target=xrefwindow id=d46789e3309 href="http://www.ncbi.nlm.nih.gov/pubmed/11372009">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3312 href="http://dx.doi.org/10.1056/NEJM200105243442103">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732756190"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3321 class=n-a></a>Bazerbachi F, Conboy EE, Mounajjed T, <i> et al.</i>: Cryptogenic Cirrhosis and Sitosterolemia: A Treatable Disease If Identified but Fatal If Missed. <i>Ann Hepatol.</i> 2017; <b>16</b>(6): 9708. <a target=xrefwindow id=d46789e3332 href="http://www.ncbi.nlm.nih.gov/pubmed/29055934">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3335 href="http://dx.doi.org/10.5604/01.3001.0010.5290">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732756190">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d46789e3349 class=n-a></a>Bacon BR, Adams PC, Kowdley KV, <i> et al.</i>: Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology.</i> 2011; <b>54</b>(1): 32843. <a target=xrefwindow id=d46789e3360 href="http://www.ncbi.nlm.nih.gov/pubmed/21452290">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3363 href="http://dx.doi.org/10.1002/hep.24330">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3367 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3149125">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d46789e3376 class=n-a></a>European Association for Study of Liver: EASL Clinical Practice Guidelines: Wilson's disease. <i>J Hepatol.</i> 2012; <b>56</b>(3): 67185. <a target=xrefwindow id=d46789e3384 href="http://www.ncbi.nlm.nih.gov/pubmed/22340672">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3387 href="http://dx.doi.org/10.1016/j.jhep.2011.11.007">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d46789e3396 class=n-a></a>Baker P II, Ayres L, Gaughan S, <i> et al.</i>: Hereditary Fructose Intolerance. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews<sup></sup> [Internet]. Seattle (WA): University of Washington, Seattle; 19932018. 2015. <a target=xrefwindow id=d46789e3404 href="http://www.ncbi.nlm.nih.gov/pubmed/26677512">PubMed Abstract </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d46789e3413 class=n-a></a>Sniderman King L, Trahms C, Scott CR: Tyrosinemia Type I. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews<sup></sup> [Internet]. Seattle (WA): University of Washington, Seattle; 19932018. 2006; [updated 2017 May 25]. <a target=xrefwindow id=d46789e3418 href="http://www.ncbi.nlm.nih.gov/pubmed/20301688">PubMed Abstract </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d46789e3427 class=n-a></a>Nagamani SCS, Erez A, Lee B: Argininosuccinate Lyase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews<sup></sup> [Internet]. Seattle (WA): University of Washington, Seattle; 19932018. 2011; [updated 2012 Feb 2]. <a target=xrefwindow id=d46789e3432 href="http://www.ncbi.nlm.nih.gov/pubmed/21290785">PubMed Abstract </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d46789e3441 class=n-a></a>Hoffman EP, Barr ML, Giovanni MA, <i> et al.</i>: Lysosomal Acid Lipase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews<sup></sup> [Internet]. Seattle (WA): University of Washington, Seattle; 19932018. 2015; [updated 2016 Sep 1]. <a target=xrefwindow id=d46789e3449 href="http://www.ncbi.nlm.nih.gov/pubmed/26225414">PubMed Abstract </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d46789e3459 class=n-a></a>European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of cholestatic liver diseases. <i>J Hepatol.</i> 2009; <b>51</b>(2): 23767. <a target=xrefwindow id=d46789e3467 href="http://www.ncbi.nlm.nih.gov/pubmed/19501929">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3470 href="http://dx.doi.org/10.1016/j.jhep.2009.04.009">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d46789e3479 class=n-a></a>Castellani C, Duff AJA, Bell SC, <i> et al.</i>: ECFS best practice guidelines: the 2018 revision. <i>J Cyst Fibros.</i> 2018; <b>17</b>(2): 15378. <a target=xrefwindow id=d46789e3490 href="http://www.ncbi.nlm.nih.gov/pubmed/29506920">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3493 href="http://dx.doi.org/10.1016/j.jcf.2018.02.006">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d46789e3502 class=n-a></a>Marshall JD, Paisey RB, Carey C, <i> et al.</i>: Alstrm Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 19932018. 2003; [updated 2012 May 31]. <a target=xrefwindow id=d46789e3507 href="http://www.ncbi.nlm.nih.gov/books/NBK1267/">Reference Source</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d46789e3516 class=n-a></a>Marshall JD, Maffei P, Collin GB, <i> et al.</i>: Alstrm syndrome: genetics and clinical overview. <i>Curr Genomics.</i> 2011; <b>12</b>(3): 22535. <a target=xrefwindow id=d46789e3527 href="http://www.ncbi.nlm.nih.gov/pubmed/22043170">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3530 href="http://dx.doi.org/10.2174/138920211795677912">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3137007">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d46789e3543 class=n-a></a>European Association for the Study of the Liver. Electronic address: <a href="mailto:easloffice@easloffice.eu">easloffice@easloffice.eu</a>: EASL Recommendations on Treatment of Hepatitis C 2016. <i>J Hepatol.</i> 2017; <b>66</b>(1): 15394. <a target=xrefwindow id=d46789e3554 href="http://www.ncbi.nlm.nih.gov/pubmed/27667367">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3557 href="http://dx.doi.org/10.1016/j.jhep.2016.09.001">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d46789e3566 class=n-a></a>European Association for the Study of the Liver. Electronic address: <a href="mailto:easloffice@easloffice.eu">easloffice@easloffice.eu</a>; European Association for the Study of the Liver: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>J Hepatol.</i> 2017; <b>67</b>(2): 37098. <a target=xrefwindow id=d46789e3577 href="http://www.ncbi.nlm.nih.gov/pubmed/28427875">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3580 href="http://dx.doi.org/10.1016/j.jhep.2017.03.021">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d46789e3590 class=n-a></a>Woodhouse CA, Patel VC, Singanayagam A, <i> et al.</i>: Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. <i>Aliment Pharmacol Ther.</i> 2018; <b>47</b>(2): 192202. <a target=xrefwindow id=d46789e3601 href="http://www.ncbi.nlm.nih.gov/pubmed/29083037">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3604 href="http://dx.doi.org/10.1111/apt.14397">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d46789e3613 class=n-a></a>European Association for the Study of the Liver. Electronic address: <a href="mailto:easloffice@easloffice.eu">easloffice@easloffice.eu</a>; European Association for the Study of the Liver: EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>J Hepatol.</i> 2017; <b>67</b>(1): 14572. <a target=xrefwindow id=d46789e3624 href="http://www.ncbi.nlm.nih.gov/pubmed/28427765">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3627 href="http://dx.doi.org/10.1016/j.jhep.2017.03.022">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d46789e3636 class=n-a></a>Wiencke K, Boberg KM: Current consensus on the management of primary sclerosing cholangitis. <i>Clin Res Hepatol Gastroenterol.</i> 2011; <b>35</b>(12): 78691. <a target=xrefwindow id=d46789e3644 href="http://www.ncbi.nlm.nih.gov/pubmed/21963085">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3647 href="http://dx.doi.org/10.1016/j.clinre.2011.04.007">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d46789e3656 class=n-a></a>European Association for the Study of Liver: EASL clinical practical guidelines: management of alcoholic liver disease. <i>J Hepatol.</i> 2012; <b>57</b>(2): 399420. <a target=xrefwindow id=d46789e3664 href="http://www.ncbi.nlm.nih.gov/pubmed/22633836">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3667 href="http://dx.doi.org/10.1016/j.jhep.2012.04.004">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d46789e3676 class=n-a></a>Hagstrm H: Alcohol, smoking and the liver disease patient. <i>Best Pract Res Clin Gastroenterol.</i> 2017; <b>31</b>(5): 53743. <a target=xrefwindow id=d46789e3684 href="http://www.ncbi.nlm.nih.gov/pubmed/29195673">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3687 href="http://dx.doi.org/10.1016/j.bpg.2017.09.003">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d46789e3696 class=n-a></a>Weersink RA, Bouma M, Burger DM, <i> et al.</i>: Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. <i>Drug Saf.</i> 2018; <b>41</b>(6): 60313. <a target=xrefwindow id=d46789e3707 href="http://www.ncbi.nlm.nih.gov/pubmed/29330714">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3710 href="http://dx.doi.org/10.1007/s40264-017-0635-x">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3714 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5966501">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d46789e3724 class=n-a></a>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical practice guidelines panel, Wendon J, <i> et al.</i>: EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. <i>J Hepatol.</i> 2017; <b>66</b>(5): 104781. <a target=xrefwindow id=d46789e3735 href="http://www.ncbi.nlm.nih.gov/pubmed/28417882">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3738 href="http://dx.doi.org/10.1016/j.jhep.2016.12.003">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d46789e3747 class=n-a></a>Djordjevic DB, Zdravkovic M, Nagorni A, <i> et al.</i>: A Critical Approach of Guideline Therapeutic Recommendations for NAFLD. <i>Curr Vasc Pharmacol.</i> 2018; <b>16</b>(3): 22838. <a target=xrefwindow id=d46789e3758 href="http://www.ncbi.nlm.nih.gov/pubmed/28676026">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3761 href="http://dx.doi.org/10.2174/1570161115666170621080228">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d46789e3770 class=n-a></a>Valla DC: Budd-Chiari syndrome/hepatic venous outflow tract obstruction. <i>Hepatol Int.</i> 2018; <b>12</b>(Suppl 1): 16880. <a target=xrefwindow id=d46789e3778 href="http://www.ncbi.nlm.nih.gov/pubmed/28685257">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3781 href="http://dx.doi.org/10.1007/s12072-017-9810-5">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d46789e3790 class=n-a></a>Xiao SH, Sun J, Chen MG: Pharmacological and immunological effects of praziquantel against <i>Schistosoma japonicum</i>: a scoping review of experimental studies. <i>Infect Dis Poverty.</i> 2018; <b>7</b>(1): 9. <a target=xrefwindow id=d46789e3801 href="http://www.ncbi.nlm.nih.gov/pubmed/29409536">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3804 href="http://dx.doi.org/10.1186/s40249-018-0391-x">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3808 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5801800">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3421959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3817 class=n-a></a>Sanyal AJ, Chalasani N, Kowdley KV, <i> et al.</i>: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. <i>N Engl J Med.</i> 2010; <b>362</b>(18): 167585. <a target=xrefwindow id=d46789e3828 href="http://www.ncbi.nlm.nih.gov/pubmed/20427778">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3831 href="http://dx.doi.org/10.1056/NEJMoa0907929">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3835 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2928471">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3421959">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d46789e3848 class=n-a></a>Canbay A, Feldstein A, Baskin-Bey E, <i> et al.</i>: The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. <i>J Pharmacol Exp Ther.</i> 2004; <b>308</b>(3): 11916. <a target=xrefwindow id=d46789e3859 href="http://www.ncbi.nlm.nih.gov/pubmed/14617689">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3862 href="http://dx.doi.org/10.1124/jpet.103.060129">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d46789e3872 class=n-a></a>Adorini L, Pruzanski M, Shapiro D: Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. <i>Drug Discov Today.</i> 2012; <b>17</b>(1718): 98897. <a target=xrefwindow id=d46789e3880 href="http://www.ncbi.nlm.nih.gov/pubmed/22652341">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3883 href="http://dx.doi.org/10.1016/j.drudis.2012.05.012">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725273573"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3892 class=n-a></a>Neuschwander-Tetri BA, Loomba R, Sanyal AJ, <i> et al.</i>: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <i>Lancet.</i> 2015; <b>385</b>(9972): 95665. <a target=xrefwindow id=d46789e3903 href="http://www.ncbi.nlm.nih.gov/pubmed/25468160">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3906 href="http://dx.doi.org/10.1016/S0140-6736(14)61933-4">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4447192">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725273573">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727636437"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e3923 class=n-a></a>Fickert P, Hirschfield GM, Denk G, <i> et al.</i>: <i>nor</i>Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>J Hepatol.</i> 2017; <b>67</b>(3): 54958. <a target=xrefwindow id=d46789e3937 href="http://www.ncbi.nlm.nih.gov/pubmed/28529147">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3941 href="http://dx.doi.org/10.1016/j.jhep.2017.05.009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727636437">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d46789e3954 class=n-a></a>Coombes JD, Swiderska-Syn M, Doll L, <i> et al.</i>: Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. <i>Gut.</i> 2015; <b>64</b>(7): 112031. <a target=xrefwindow id=d46789e3965 href="http://www.ncbi.nlm.nih.gov/pubmed/24902765">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3968 href="http://dx.doi.org/10.1136/gutjnl-2013-306484">Publisher Full Text </a> | <a target=xrefwindow id=d46789e3972 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4487727">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d46789e3981 class=n-a></a>Marra F, Tacke F: Roles for chemokines in liver disease. <i>Gastroenterol.</i> 2014; <b>147</b>(3): 577594.e1. <a target=xrefwindow id=d46789e3989 href="http://www.ncbi.nlm.nih.gov/pubmed/25066692">PubMed Abstract </a> | <a target=xrefwindow id=d46789e3992 href="http://dx.doi.org/10.1053/j.gastro.2014.06.043">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d46789e4001 class=n-a></a>Baeck C, Wehr A, Karlmark KR, <i> et al.</i>: Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. <i>Gut.</i> 2012; <b>61</b>(3): 41626. <a target=xrefwindow id=d46789e4012 href="http://www.ncbi.nlm.nih.gov/pubmed/21813474">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4015 href="http://dx.doi.org/10.1136/gutjnl-2011-300304">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/714297813"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4025 class=n-a></a>Kong X, Feng D, Wang H, <i> et al.</i>: Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. <i>Hepatol.</i> 2012; <b>56</b>(3): 11509. <a target=xrefwindow id=d46789e4036 href="http://www.ncbi.nlm.nih.gov/pubmed/22473749">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4039 href="http://dx.doi.org/10.1002/hep.25744">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3394879">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/714297813">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d46789e4056 class=n-a></a>Cox N, Pilling D, Gomer RH: Serum amyloid P: a systemic regulator of the innate immune response. <i>J Leukoc Biol.</i> 2014; <b>96</b>(5): 73943. <a target=xrefwindow id=d46789e4064 href="http://www.ncbi.nlm.nih.gov/pubmed/24804675">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4067 href="http://dx.doi.org/10.1189/jlb.1MR0114-068R">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726177805"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4076 class=n-a></a>Bottazzi B, Inforzato A, Messa M, <i> et al.</i>: The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. <i>J Hepatol.</i> 2016; <b>64</b>(6): 141627. <a target=xrefwindow id=d46789e4087 href="http://www.ncbi.nlm.nih.gov/pubmed/26921689">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4090 href="http://dx.doi.org/10.1016/j.jhep.2016.02.029">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4094 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5414834">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726177805">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717990502"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4107 class=n-a></a>Kim KH, Chen CC, Monzon RI, <i> et al.</i>: Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. <i>Mol Cell Biol.</i> 2013; <b>33</b>(10): 207890. <a target=xrefwindow id=d46789e4118 href="http://www.ncbi.nlm.nih.gov/pubmed/23508104">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4121 href="http://dx.doi.org/10.1128/MCB.00049-13">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4125 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3647960">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717990502">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d46789e4138 class=n-a></a>Borkham-Kamphorst E, Schaffrath C, van de Leur E, <i> et al.</i>: The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF- signaling. <i>Biochim Biophys Acta.</i> 2014; <b>1843</b>(5): 90214. <a target=xrefwindow id=d46789e4149 href="http://www.ncbi.nlm.nih.gov/pubmed/24487063">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4152 href="http://dx.doi.org/10.1016/j.bbamcr.2014.01.023">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d46789e4161 class=n-a></a>Ramachandran P, Pellicoro A, Vernon MA, <i> et al.</i>: Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. <i>Proc Natl Acad Sci U S A.</i> 2012; <b>109</b>(46): E318695. <a target=xrefwindow id=d46789e4172 href="http://www.ncbi.nlm.nih.gov/pubmed/23100531">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4175 href="http://dx.doi.org/10.1073/pnas.1119964109">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4179 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3503234">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d46789e4189 class=n-a></a>Borkham-Kamphorst E, Weiskirchen R: The PDGF system and its antagonists in liver fibrosis. <i>Cytokine Growth Factor Rev.</i> 2016; <b>28</b>: 5361. <a target=xrefwindow id=d46789e4197 href="http://www.ncbi.nlm.nih.gov/pubmed/26547628">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4200 href="http://dx.doi.org/10.1016/j.cytogfr.2015.10.002">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d46789e4209 class=n-a></a>Murphy FR, Issa R, Zhou X, <i> et al.</i>: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. <i>J Biol Chem.</i> 2002; <b>277</b>(13): 1106976. <a target=xrefwindow id=d46789e4220 href="http://www.ncbi.nlm.nih.gov/pubmed/11796725">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4223 href="http://dx.doi.org/10.1074/jbc.M111490200">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d46789e4232 class=n-a></a>Zhou X, Hovell CJ, Pawley S, <i> et al.</i>: Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. <i>Liver Int.</i> 2004; <b>24</b>(5): 492501. <a target=xrefwindow id=d46789e4243 href="http://www.ncbi.nlm.nih.gov/pubmed/15482348">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4246 href="http://dx.doi.org/10.1111/j.1478-3231.2004.0946.x">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5492957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4255 class=n-a></a>Barry-Hamilton V, Spangler R, Marshall D, <i> et al.</i>: Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. <i>Nat Med.</i> 2010; <b>16</b>(9): 100917. <a target=xrefwindow id=d46789e4266 href="http://www.ncbi.nlm.nih.gov/pubmed/20818376">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4269 href="http://dx.doi.org/10.1038/nm.2208">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5492957">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727194600"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4282 class=n-a></a>Ikenaga N, Peng ZW, Vaid KA, <i> et al.</i>: Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. <i>Gut.</i> 2017; <b>66</b>(9): 1697708. <a target=xrefwindow id=d46789e4293 href="http://www.ncbi.nlm.nih.gov/pubmed/28073888">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4296 href="http://dx.doi.org/10.1136/gutjnl-2016-312473">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4300 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5561383">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727194600">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d46789e4313 class=n-a></a>Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. <i>J Clin Invest.</i> 2007; <b>117</b>(3): 53948. <a target=xrefwindow id=d46789e4321 href="http://www.ncbi.nlm.nih.gov/pubmed/17332881">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4324 href="http://dx.doi.org/10.1172/JCI30542">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4327 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1804370">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d46789e4337 class=n-a></a>Pellicoro A, Ramachandran P, Iredale JP, <i> et al.</i>: Liver fibrosis and repair: immune regulation of wound healing in a solid organ. <i>Nat Rev Immunol.</i> 2014; <b>14</b>(3): 18194. <a target=xrefwindow id=d46789e4348 href="http://www.ncbi.nlm.nih.gov/pubmed/24566915">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4351 href="http://dx.doi.org/10.1038/nri3623">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732084352"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4360 class=n-a></a>Garca-Lezana T, Raurell I, Bravo M, <i> et al.</i>: Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. <i>Hepatology.</i> 2018; <b>67</b>(4): 148598. <a target=xrefwindow id=d46789e4371 href="http://www.ncbi.nlm.nih.gov/pubmed/29113028">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4374 href="http://dx.doi.org/10.1002/hep.29646">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732084352">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727038183"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4387 class=n-a></a>Ferrere G, Wrzosek L, Cailleux F, <i> et al.</i>: Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. <i>J Hepatol.</i> 2017; <b>66</b>(4): 80615. <a target=xrefwindow id=d46789e4398 href="http://www.ncbi.nlm.nih.gov/pubmed/27890791">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4401 href="http://dx.doi.org/10.1016/j.jhep.2016.11.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727038183">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726028173"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4414 class=n-a></a>Cerini F, Vilaseca M, Lafoz E, <i> et al.</i>: Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. <i>J Hepatol.</i> 2016; <b>64</b>(4): 83442. <a target=xrefwindow id=d46789e4425 href="http://www.ncbi.nlm.nih.gov/pubmed/26686269">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4428 href="http://dx.doi.org/10.1016/j.jhep.2015.12.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726028173">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727762992"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4441 class=n-a></a>Fortea JI, Zipprich A, Fernandez-Mena C, <i> et al.</i>: Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. <i>Liver Int.</i> 2018; <b>38</b>(1): 10212. <a target=xrefwindow id=d46789e4452 href="http://www.ncbi.nlm.nih.gov/pubmed/28665498">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4455 href="http://dx.doi.org/10.1111/liv.13510">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727762992">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717953176"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4468 class=n-a></a>Villa E, Camm C, Marietta M, <i> et al.</i>: Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. <i>Gastroenterology.</i> 2012; <b>143</b>(5): 12531260.e4. <a target=xrefwindow id=d46789e4479 href="http://www.ncbi.nlm.nih.gov/pubmed/22819864">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4482 href="http://dx.doi.org/10.1053/j.gastro.2012.07.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717953176">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d46789e4496 class=n-a></a>Schon HT, Weiskirchen R: Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury. <i>Front Pharmacol.</i> 2016; <b>7</b>: 283. <a target=xrefwindow id=d46789e4504 href="http://www.ncbi.nlm.nih.gov/pubmed/27625607">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4507 href="http://dx.doi.org/10.3389/fphar.2016.00283">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5003891">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d46789e4519 class=n-a></a>Ouchi N, Parker JL, Lugus JJ, <i> et al.</i>: Adipokines in inflammation and metabolic disease. <i>Nat Rev Immunol.</i> 2011; <b>11</b>(2): 8597. <a target=xrefwindow id=d46789e4530 href="http://www.ncbi.nlm.nih.gov/pubmed/21252989">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4533 href="http://dx.doi.org/10.1038/nri2921">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4537 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3518031">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d46789e4546 class=n-a></a>Ringseis R, Eder K, Mooren FC, <i> et al.</i>: Metabolic signals and innate immune activation in obesity and exercise. <i>Exerc Immunol Rev.</i> 2015; <b>21</b>: 5868. <a target=xrefwindow id=d46789e4557 href="http://www.ncbi.nlm.nih.gov/pubmed/25825956">PubMed Abstract </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727348554"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4566 class=n-a></a>Musso G, Cassader M, Paschetta E, <i> et al.</i>: Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. <i>JAMA Intern Med.</i> 2017; <b>177</b>(5): 63340. <a target=xrefwindow id=d46789e4577 href="http://www.ncbi.nlm.nih.gov/pubmed/28241279">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4580 href="http://dx.doi.org/10.1001/jamainternmed.2016.9607">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4584 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5470366">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727348554">F1000 Recommendation</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d46789e4597 class=n-a></a>Zhang S, Wang J, Liu Q, <i> et al.</i>: Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. <i>J Hepatol.</i> 2009; <b>51</b>(2): 3808. <a target=xrefwindow id=d46789e4608 href="http://www.ncbi.nlm.nih.gov/pubmed/19501927">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4611 href="http://dx.doi.org/10.1016/j.jhep.2009.03.025">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d46789e4620 class=n-a></a>Trevaskis JL, Griffin PS, Wittmer C, <i> et al.</i>: Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2012; <b>302</b>(8): G76272. <a target=xrefwindow id=d46789e4631 href="http://www.ncbi.nlm.nih.gov/pubmed/22268099">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4634 href="http://dx.doi.org/10.1152/ajpgi.00476.2011">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d46789e4644 class=n-a></a>Jouihan H, Will S, Guionaud S, <i> et al.</i>: Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. <i>Mol Metab.</i> 2017; <b>6</b>(11): 136070. <a target=xrefwindow id=d46789e4655 href="http://www.ncbi.nlm.nih.gov/pubmed/29107284">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4658 href="http://dx.doi.org/10.1016/j.molmet.2017.09.001">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4662 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5681275">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d46789e4671 class=n-a></a>Sato K, Gosho M, Yamamoto T, <i> et al.</i>: Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. <i>Nutrition.</i> 2015; <b>31</b>(78): 92330. <a target=xrefwindow id=d46789e4682 href="http://www.ncbi.nlm.nih.gov/pubmed/26059365">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4685 href="http://dx.doi.org/10.1016/j.nut.2014.11.018">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731077803"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4694 class=n-a></a>Loomba R, Lawitz E, Mantry PS, <i> et al.</i>: The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. <i>Hepatology.</i> 2017. <a target=xrefwindow id=d46789e4702 href="http://www.ncbi.nlm.nih.gov/pubmed/28892558">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4705 href="http://dx.doi.org/10.1002/hep.29514">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4708 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5814892">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731077803">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732323132"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4721 class=n-a></a>Sumida Y, Yoneda M: Current and future pharmacological therapies for NAFLD/NASH. <i>J Gastroenterol.</i> 2018; <b>53</b>(3): 36276. <a target=xrefwindow id=d46789e4729 href="http://www.ncbi.nlm.nih.gov/pubmed/29247356">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4732 href="http://dx.doi.org/10.1007/s00535-017-1415-1">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4735 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5847174">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732323132">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d46789e4748 class=n-a></a>Puengel T, Krenkel O, Kohlhepp M, <i> et al.</i>: Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. <i>PLoS One.</i> 2017; <b>12</b>(9): e0184694. <a target=xrefwindow id=d46789e4759 href="http://www.ncbi.nlm.nih.gov/pubmed/28910354">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4762 href="http://dx.doi.org/10.1371/journal.pone.0184694">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4766 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5598992">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d46789e4775 class=n-a></a>Krenkel O, Puengel T, Govaere O, <i> et al.</i>: Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. <i>Hepatology.</i> 2018; <b>67</b>(4): 127083. <a target=xrefwindow id=d46789e4786 href="http://www.ncbi.nlm.nih.gov/pubmed/28940700">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4789 href="http://dx.doi.org/10.1002/hep.29544">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d46789e4799 class=n-a></a>Friedman SL, Ratziu V, Harrison SA, <i> et al.</i>: A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology.</i> 2018; <b>67</b>(5): 175467. <a target=xrefwindow id=d46789e4810 href="http://www.ncbi.nlm.nih.gov/pubmed/28833331">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4813 href="http://dx.doi.org/10.1002/hep.29477">Publisher Full Text </a> | <a target=xrefwindow id=d46789e4817 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5947654">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726760174"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d46789e4826 class=n-a></a>Rotman Y, Sanyal AJ: Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. <i>Gut.</i> 2017; <b>66</b>(1): 18090. <a target=xrefwindow id=d46789e4834 href="http://www.ncbi.nlm.nih.gov/pubmed/27646933">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4837 href="http://dx.doi.org/10.1136/gutjnl-2016-312431">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726760174">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d46789e4850 class=n-a></a>Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, <i> et al.</i>: Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology.</i> 2015; <b>149</b>(2): 36778.e5; quiz e145. <a target=xrefwindow id=d46789e4861 href="http://www.ncbi.nlm.nih.gov/pubmed/25865049">PubMed Abstract </a> | <a target=xrefwindow id=d46789e4864 href="http://dx.doi.org/10.1053/j.gastro.2015.04.005">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jun 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-921/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-921/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Pauwelsstra&szlig;e 30, Germany<br/> <sup>2</sup> Department of Medicine III, RWTH University Hospital Aachen, D-52074 Aachen, Pauwelsstra&szlig;e 30, Germany<br/> <p> <div class=margin-bottom> Ralf Weiskirchen <br/> <span>Roles: </span> Conceptualization, Supervision, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Sabine Weiskirchen <br/> <span>Roles: </span> Visualization, Writing  Review & Editing </div> <div class=margin-bottom> Frank Tacke <br/> <span>Roles: </span> Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-921/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 27 Jun 2018, 7:921 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14841.1">https://doi.org/10.12688/f1000research.14841.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2018 Weiskirchen R <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16154 data-id=14841 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14841.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-921/v1/pdf?article_uuid=a25c7414-568d-4b02-b517-5055f12ed497" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14841.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Weiskirchen R, Weiskirchen S and Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):921 (<a href="https://doi.org/10.12688/f1000research.14841.1" target=_blank>https://doi.org/10.12688/f1000research.14841.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14841 id=mobile-track-article-signin-14841 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14841?target=/articles/7-921/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16154 /> <input name=articleId type=hidden value=14841 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Leo van Grunsven</strong>, Department of Basic Biomedical Sciences, Liver Cell Biology Laboratory, Vrije Universiteit Brussel, Belgium </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Nahum M&eacute;ndez-S&aacute;nchez</strong>, Liver Research Unit. Medica Sur Clinic & Foundation, Mexico </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jun 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-921/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-921/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=35869-35411></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=35872-35410></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-921/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>27 Jun 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Leo van Grunsven</strong>, Department of Basic Biomedical Sciences, Liver Cell Biology Laboratory, Vrije Universiteit Brussel, Belgium </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Nahum M&eacute;ndez-S&aacute;nchez</strong>, Liver Research Unit. Medica Sur Clinic & Foundation, Mexico </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-921/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-921/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding liver fibrosis:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-921/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-921/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-921/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Weiskirchen R et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-921/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-921",
            templates : {
                twitter : "Recent advances in understanding liver fibrosis: bridging basic.... Weiskirchen R et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-921/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14841/16154")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16154");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "35410": 0,
                           "35411": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "4fdbe22f-1fbe-4258-8ccc-204691cc4faa";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-921.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-921.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-921.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-921.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-921.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>